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CHARACTERIZATION OF PROMOTER REGIONS OF PAROTID GLAND 
GENES 
Sara M. Perez 
July 9, 2013 
BACKGROUND: Salivary secretion aids in digestion, host defense, and 
lubrication. Parotid salivary gland defects from Sjogren’s Syndrome affect more 
than one million Americans and cause dry mouth leading to oral disease. The 
Amylase 1 gene and the PSP gene are markers of parotid gland differentiation 
and indicate normal parotid gland function. Transcriptional activators of genes 
involved in parotid differentiation have not been characterized.   
HYPOTHESIS: Characterizing transcriptional activating sites in gene promoter 
regions will confirm upstream activating factors in bioinformatic network 
pathways. 
METHODS: Two promoter regions of mouse amylase 1 were identified using the 
ECR Browser, PCR amplified and ligated into a pGL4.10 luciferase vector. 
Transcriptional repressor binding sites were identified and removed from the 1 
kbp region, followed by PCR amplification to produce fragments that were ligated 
into the minimal promoter pGL4.23 luciferase vector. These promoter clones 
were then transfected into three cell lines and tested for promoter activity.
! #!
 Bioinformatic analysis of microarray data determined correlations between 
increased transcription factor expression and markers of parotid differentiation. A 
hypothetical transcription factor network was created. Two interactions from the 
network predicted to activate the NUPR1 gene were Cited2/p300 and 
IRF2/PCAF. Mist1 was suggested to activate the PSP gene based on the 
hypothetical network. The promoter regions of NUPR1 and PSP were transfected 
into a parotid acinar cell line, and promoter activity was determined using dual 
luciferase assays with an internal Renilla control. 
RESULTS: The four amylase promoter clones, R1, R2-R1, 900bp, and 700bp 
were repressed as compared to a promoterless negative control, pGL4.10. The 
NUPR1 promoter was not activated by the co-transfected combination of 
Cited2/p300 or IRF2/PCAF. The PSP promoter alone was not activated by Mist1 
transcription factor. However, PSP was activated when Mist1 was co-transfected 
with Tcf3 transcription factor and when intron regions containing E-box binding 
sites were added to the PSP promoter clone.  
CONCLUSION: Amylase 1 was not activated in the regions tested; therefore the 
active regions of the amylase 1 gene must be outside the 3 kbp region tested. 
NUPR1 is not activated by the predicted interactions of Cited2/p300 or 
IRF2/PCAF, so the results do not support the hypothetical transcription factor 
network. The PSP proximal promoter is not activated by Mist1, but a PSP 
promoter + intron construct is activated when the transcription factor Tcf3 + Mist1 
are co-transfected.  
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 In mammals, there are three major types of salivary glands: the parotid 
gland, the submandibular gland, and the sublingual glands; and there are minor 
glands as well [1, 2]. The function of salivary glands is to secrete components 
that make up saliva. A healthy adult secretes, on average, 500-1500 mL of saliva 
per day [2, 3]. Saliva secretion can by stimulated by smell, taste, chewing, 
psychological and hormonal status, drugs, age, hereditary influences, oral 
hygiene, and physical activity.  
Secretory cells in the salivary glands are specialized epithelial cells, and 
are classified as serous cells, which secrete a watery fluid, or mucous cells which 
secrete a mucin-rich fluid [2]. Each salivary gland secretes the components of 
saliva from a cluster of cells termed acini, the main secretory unit. Acinar cell 
secretions include water, electrolytes, mucus, enzymes, and other proteins [2]. 
Alpha-amylase is an enzyme secreted by acinar cells that breaks down starch 
into glucose. Ductal cells are also contained in salivary glands and are involved 
in modifying primary saliva and transporting saliva to the oral cavity [4].  
Saliva is either secreted in response to a neural stimulus (regulated 
secretion) or constitutively secreted from the apical membrane of acinar cells [5]. 
The saliva composition from regulated or constitutive secretion varies [2]. 
Regulated secretion is distinguished by large, dense secretory granules that 
#"
contain 80 – 90% of the total proteins secreted from parotid acinar cells [6]. 
Constitutively secreted proteins are different from regulated secretion in that they 
are contained in immature secretory granules that contain lysosomal and other 
non-salivary proteins.  
Water making up saliva crosses epithelial cells in an anion dependent 
process [1]. Vesicles in the cell bring membrane ion transport proteins to the cell 
membrane, and these proteins allow the movement of sodium, chloride, and 
bicarbonate into the acini lumen [7]. The transport of these anions into acini 
creates an osmotic gradient allowing the transport of water into the lumen. Water 
helps complete saliva formation. Since water is a required component of saliva, 
salivary glands require very high fluid transport per unit surface area [8, 9]. Water 
channels called aquaporins have been found in salivary cells and aid in water 
transport. Aquaporin-5 is located in the apical membrane of salivary cells. A 
knockout model of aquaporin-5 decreased salivary fluid secretion by 50%, 
indicating its importance in saliva formation [8].  
Each type of salivary gland secretes a different type of saliva due to 
different glandular content of serous cells and mucous cells [2]. The parotid gland 
is located in subcutaneous tissue of the face overlying the mandibular ramus and 
secretes serous type saliva containing the most abundant proteins of saliva: 
amylase, proline-rich proteins, and parotid secretory protein (PSP) [1-3, 5]. The 
sublingual gland is beneath the tongue and secretes a mucus substance. The 
submandibular gland is found beneath the lower jaws and secretes a 
combination of proteins and mucus. Other components present in the mixed 
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saliva of the mouth, but not produced by salivary glands, are gingival crevicular 
fluid, serum transudate from mucosa and inflammatory sites, epithelial and 
immune cells, and microorganisms [2].  
Saliva has a wide array of functions that protect the mouth against 
infection by microorganisms. Saliva aids in host defense, digestion, and 
lubrication [10]. Saliva lubricates the hard and soft oral surfaces with a saliva film 
containing mucins, proline-rich-proteins (PRP’s), and water allowing for ease of 
speech, mastication, and swallowing [11]. Saliva helps neutralize oral cavity pH 
after food ingestion and removes food and microorganisms to maintain oral 
hygiene [2]. Mucins in saliva bind to bacteria and prevent them from adhering to 
the tooth enamel. Lysozyme in saliva also lyses bacteria and prevents rampant 
growth of oral bacterial colonies. The binding of mucins and the action of 
lysozymes, in combination with histatins and other proteins, aid in the 
antibacterial and antiviral activities of saliva [12].  
 Salivary glands begin development in the embryo and go through 
branching morphogenesis [13]. In the rat, parotid gland development begins 
around the fourteenth day of gestation [14]. From this point the oral epithelium 
thickens and grows into the mesenchyme as a bud. Epithelial cells proliferate 
and begin the process of repeated branching and cleft formation. The lumen 
develops and the gland differentiates into acinar and ductal components until the 
mature parotid gland is formed [13, 14].  
Parotid gland development can be divided into four stages. The first stage 
is the prenatal period beginning at the initiation of gland development until birth. 
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This period is characterized by cell proliferation, epithelial branching with terminal 
clusters and ductal structures, and an absence of secretory granules [14]. The 
next stage, neonatal period, is characterized by acinar cells differentiating to 
active secretory cells. The transitional period has the complete adult morphology 
and secretory proteins found in an adult gland. Acinar cells continue to grow in 
size, rough endoplasmic reticulum content, and secretory granules. Ducts form 
their elongated branching structure. The fully mature gland is found in the adult 
period of parotid development.  
 Infection, inflammation, head and neck radiation therapy, medications, and 
Sjögren’s Syndrome (SS) can compromise salivary gland function [5, 15]. 
Sjögren’s Syndrome is an autoimmune disease affecting the salivary and lacrimal 
glands characterized by lymphoplasmocytic infiltration of the tissues [16]. 
Sjögren’s Syndrome can be classified as primary SS or secondary SS, 
depending on the absence or presence of other connective tissue diseases. 
About one-third of primary SS patients will develop malignant lymphoma. 
Characteristic symptoms of Sjögren’s Syndrome include decreased tear 
production by the lacrimal glands and xerostomia, or dry mouth, caused by 
salivary gland dysfunction [17]. Xerostomia causes issues with mastication, 
swallowing, and taste [3, 15]. More importantly, xerostomia can affect oral health 
causing increased oral disease, such as periodontitis, and dental caries.  
Diagnosing SS has been, and continues to be, a challenge. There are two 
factors that clinicians must deal with when diagnosing a patient with SS: 
assessing the ocular and salivary components of the disease and distinguishing 
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between primary and secondary SS variants [18]. These two factors have led to 
classification criteria that are not used consistently from clinician to clinician 
around the world [18]. The American-European Group has revised and 
established diagnostic criteria for SS [18, 19]. At least four out of six subjective 
criteria and three out of four objective criteria must be met to diagnose SS. These 
criteria include subjective and objective ocular dryness, subjective and objective 
oral dryness, presence of Sjögren-specific antibody A (SSA) or Ro, and/or 
Sjögren-specific antibody B (SSB) or La [18, 19].  
Diagnostic testing for SS includes looking at saliva components 
(sialochemistry) such as determining the presence of autoantibodies in saliva, 
and/or looking at salivary flow rates (sialometry) of whole saliva or glandular 
saliva [2, 20]. Limitations to analyzing saliva composition is that this can only 
diagnose SS when major changes occur, and sialochemical analysis cannot 
always be performed because amounts of saliva are insufficient to test [20]. 
Another test to assess salivary gland function is an invasive biopsy of minor 
salivary gland tissue. This allows clinicians to evaluate the degree of 
lymphoplasmocytic infiltration within the harvested glands and is an important 
objective criterion in the diagnosis of SS [18]. The risks with biopsy are the 
patient’s lip can be left numb after the procedure and false negatives can occur.  
 Once a patient is diagnosed with SS, the goal is to restore salivary gland 
function. If there is still viable glandular tissue, cholinergic medications such as 
pilocarpine and cevimeline will stimulate saliva production [3]. In addition, 
artificial salivas and other oral hygiene products can help keep the mouth moist 
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but some patients still struggle to find relief. Research is currently in progress 
looking at salivary gland regeneration by expressing growth factors and 
transcription factors expressed during development. Also, gene therapy using the 
adenovirus-mediated water channel (aquaporin-1, AQP1) gene has shown 
increased salivary flow rate in rats [3, 21]. The AdhAQP1 gene was expressed in 
a miniature pig model that showed dose-dependent, transient increase in parotid 
salivary flow [3, 22]. Baum et. al. have begun a Phase I clinical trial testing 
AdhAQP1 in human subjects [23]. Through the first 42 days of this trial his group 
has found the use of an Ad5 vector to be safe, an increase in parotid flow rate, 
and the peak salivary flow rate is variable and occurs later than animal studies 
[23]. This clinical trial holds hope for the use of gene therapy for parotid gland 
dysfunction.   
The lack of sufficient treatment for salivary gland dysfunction and initial 
research for gene therapies support aims focusing to confirm gene expression 
and transcription factor pathways involved during parotid gland differentiation. 
These pathways could shed light on new diagnostics or therapeutics to help 
patients suffering from parotid gland ablation. The research described and data 
provided in this thesis was aimed at confirming a few of the many regulatory 
pathways involved in parotid gland differentiation. The following sections will 
describe genes that are markers of parotid gland terminal differentiation and 
some of the transcription factors that regulate these genes.  
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TRANSCRIPTION FACTORS EXPRESSED DURING PAROTID 
DIFFERENTIATION 
 Molecular mechanisms are involved in parotid gland differentiation. Dr. 
Venkatesh Srirangapatnam performed analysis of mRNA expression across the 
process of rat parotid gland development. The heat map created from this 
analysis observed changes of mRNA expression of transcription factors from 
embryonic days to postnatal days (Figure 1). From this data, statistical analysis 
combined similarly expressed groups of transcription factors in a hierarchical 
clustering. This clustering observed four distinct stages of parotid differentiation. 
The model suggested by the clustering is that transcription factors increased in 
the first cluster turn on expression of transcription factors in subsequent clusters 
eventually leading to activation of expression of gene markers of parotid 
differentiation, such as amylase I and PSP. My goal has been to contribute to 
defining the progressive regulatory steps that lead to expression of markers of 
differentiation of the parotid.  
 The mRNA analysis, along with Ingenuity Pathway Assist (IPA) analysis, 
was used to create a hypothetical network of transcription factors involved in 
parotid differentiation. IPA is a system that analyzes a list of genes and helps 
model gene interactions using a knowledge base of reported gene function [24]. 
Gene interactions generated by IPA were depicted in a hypothetical transcription 
factor network (Figure 2). Some of these interactions were validated in the 
laboratory, but some still needed to be confirmed. These pathways are the basis 
of the research presented in this thesis. The goal of this research was to 
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characterize promoter regions of parotid gland gene markers by validating the 
transcription factor networks designated A, B, and C on the hypothetical 
transcription factor network in Figure 2. The specific goals were to test the 
promoter regulation of mus Amylase-1 gene, rat NUPR1 gene, and rat PSP gene 
in a parotid acinar cell line. Analysis of transcription factor expression helped 
suggest different regulatory pathways in parotid gland differentiation. This mRNA 
expression analysis aided in selecting the gene promoters and the transcription 
factor interactions studied. Also, amylase-1 and PSP have been cited in the 
literature numerous times as markers of differentiated parotid acinar cells, so it 
was important to identify the active promoter regions and/or activating 
transcription factors involved in the expression of these genes. The goal of 













Figure 1: Transcription factor expression during parotid differentiation. 
 
Figure 1: Heat map of transcription factors expressed during parotid 
differentiation. Each column represents an individual transcription factor mRNA. 
Each row represents an individual rat parotid gland time point starting at 
embryonic day 18 (E18) and ending at postnatal day 25 (P25), represented on 
the right side of the heat map. The left side of the heat map is a hierarchical 
clustering of similarly expressed transcription factors. Parotid differentiation can 
be clustered in four groups according to this analysis. Transcription factors 
expressed in low concentrations are represented by green and those expressed 
in higher concentrations are represented by red. The model is that in some cases 






























cluster and continues until the transcription factors eventually turn on markers of 






















Figure 2: Hypothetical transcription factor network regulating parotid 
differentiation. 
 
Figure 2: This network shows transcriptional activators regulating parotid 
differentiation based on Ingenuity Pathway Assist (IPA) analysis. Transcription 
factor genes expressed differentially in parotid differentiation were of interest and 
this pathway was created. The green arrows represent confirmed interactions. 
The black arrows represent interactions that still need to be confirmed. 
Experiments performed to confirm some of these interactions included testing the 

























AMYLASE I GENE 
 Amylase is a marker of terminal differentiation of the parotid gland and is a 
gene of interest in this research. Amylase has two genes located on mouse 
chromosome three [25, 26]. The first locus corresponds to Amy-1, which is 
strongly expressed in the salivary gland, and the second locus is Amy-2, which is 
expressed in the pancreas. The Amy-1 gene is expressed as two different mRNA 
products with one in the parotid gland and the other in the liver. The coding 
sequence for liver and parotid alpha-amylase is the same with the 3’ non-
translated region and part of the 5’ non-translated region being identical. The 
extreme 5’ leader sequence is unrelated with no sequence homology found 
between parotid alpha-amylase and liver alpha-amylase. Mouse Amy-2 shares 
90% homology to parotid and liver alpha-amylase, but it has a very short 5’ 
untranslated region and the coding region is shorter [27]. Amy-1 and Amy-2 both 
have ten exons coding for alpha-amylase. However, Amy-1 has two exons 
containing 5’ untranslated leader sequence corresponding to the parotid alpha-
amylase exon that is separated from the first coding exon by 7.8 kb, and the liver 
alpha-amylase exon that is 4.9 kb from the first coding exon. Alpha-amylase 
mRNA is about 10-fold less in parotid acinar cells than pancreatic cells [28]. Liver 
alpha-amylase levels are even lower making up 1/100th of parotid levels and 
1/1000th of pancreatic levels. Pancreatic amylase is expressed in all mammals, 
but salivary amylase is specific to primates, rodents, and lagomorphs [29].   
A chapter written describing murine alpha-amylase describes two Amy-1 
promoters with tissue specific expression, the parotid promoter, PP, and the liver 
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promoter, PL [28]. Endogenous RNA was isolated from rat liver and parotid cells 
[26]. Rat liver and parotid mRNA were fractionated on a gel and hybridized to a 
probe complementary to the first exon of the liver-specific mouse Amy-1 mRNA. 
Liver-specific amylase transcripts were detected, but parotid-specific transcripts 
were not detected. Next, rat liver and parotid mRNA was hybridized to a primer 
complementary to most of the coding region of the parotid mRNA. This probe 
detected large amounts of parotid-specific alpha-amylase transcripts. These 
results confirm that amylase is being specifically transcribed in the liver and 
parotid glands. Primer extensions assays used a radioactive labeled probe that 
was hybridized to rat parotid mRNA and was extended to determine the location 
of the transcription start site for parotid Amy-1 in the mouse and rat [26]. 
Experiments done in vitro helped validate the transcription start sites of the 
parotid promoter and the liver promoter. Results from these experiments showed 
that polymerase II molecules involved in transcription initiated at two different 
start sites. Since the proximal upstream region to the transcription start site is 
usually assumed to be the promoter, the parotid and liver amylase promoters 
were predicted to be in these regions.  
The parotid promoter was observed to be about 30-fold stronger than the 
liver promoter in hepatocytes, giving the terms “strong promoter” to the parotid 
(Pp) and “weak promoter” to the liver (PL). The liver promoter was active in liver, 
parotid, and pancreas with no apparent physiological relevance of the liver 
transcript in the parotid or pancreas. The transcriptional activity of the parotid 
promoter increases alpha-amylase levels about 100-fold in the saliva of weaning 
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rats to make up about 97% of amylase transcripts in adult saliva [30]. The liver 
promoter is active soon after birth and by two weeks of age the activity of the 
liver promoter is that which is found in the adult parotid. Transcripts produced 
from PP are found in all acinar cells at three weeks of age.  
The activity of mouse PP and PL was tested by transfecting the 1 kbp 
proximal promoter region in cell lines that do not have endogenous Amy-1 
expression [28]. The chapter mentioned above describing murine alpha-amylase 
noted (but did not present data) on the activity of PL and PP. PL was active in 
stably transfected mouse L cells, and was transiently expressed and activated in 
many of the cell lines tested. Importantly, the endogenous PP had been found to 
be about 30-fold in vivo more efficient than PL, but transfected PP promoter was 
not active in any cell lines tested. The conclusion made from these experiments 
was that PP is more controlled than PL, probably due to PL’s lower tissue 
specificity and to its activity in less differentiated parotid acinar precursor cells. 
Also, the results suggest that PP might be regulated by a repressive mechanism. 
An unpublished observation mentioned by Schibler in the murine alpha-amylase 
chapter was that the progressive deletion of the 5’ flanking region of PP found 
that by removing nucleotides upstream of position -300 relieves the 
transcriptional repression leading to promoter activation [28].  
The human salivary amylase promoter was active in human 
submandibular gland-derived cell line (HSG) [31]. The human 1 kbp amylase 
promoter was inserted in an adenovirus containing a luciferase reporter gene. 
Adenoviral infection of the HSG cell type with the human 1 kbp promoter 
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construct observed that this promoter is active. The conclusion based on the 
transfection studies just described is that the human parotid gland and the 
murine parotid gland may involve different mechanisms that activate the parotid 
amylase promoter.   
 Rat and mouse Amy-1 have some similarities and differences in gene 
structure and in gene and tissue expression [28]. The similarities between the 
species are they both contain two promoters, PP and PL, there is homology of 
sequences around PP and PL, and PP expression is exclusive to parotid acinar 
cells. The differences between the two species are that PP and PL are farther 
apart in the rat, there is a different PL start site used, the rat splice donor sites are 
downstream of the mouse site, and the mRNA is about 300 nucleotides longer 
than the mouse. The PL is specific to the liver and is not detected in rat parotid 
acinar cells.  
 Salivary alpha-amylase protein has various functions in the oral cavity 
ranging from enzymatic activity to interactions with bacterial species as well as 
making up other components that aid in tooth formation. Salivary amylase is an 
abundant enzyme produced primarily from serous cells of the parotid. Human 
saliva contains on average 0.04 – 0.4 mg/mL of amylase constituting up to 5% of 
the total salivary protein content [32]. The enzymatic activity of salivary alpha-
amylase protein is to hydrolyze food starch into maltose and glucose [33]. 
Specifically salivary alpha-amylase hydrolyzes !-1,4-glucosidic bonds in starch, 
glycogen, and other polysaccharides starting in the oral cavity [34]. Amylase 
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enzyme has been shown to function as a monomeric or dimeric protein and 
requires calcium and chloride ions for full enzymatic function [35, 36].  
Salivary amylase indirectly and directly affects oral biofilms by providing 
carbohydrate nutrients to bacteria, promoting bacterial adhesion to the tooth 
surface, and binding to oral streptococci at secondary oligosaccharide sites [34, 
36, 37]. When tooth surfaces are initially exposed to the oral environment, a thin 
film absent of cells is formed called the acquired enamel pellicle (AEP) [32]. 
Amylase has been found as a component of the AEP.  
 Amylase is highly expressed in the adult parotid gland, so it is important to 
understand how this gene is regulated [30]. Previous studies found the human 
proximal parotid amylase promoter to be active, however, recent experiments 
have observed repressed activity when testing the mouse and rat proximal 1kbp 
promoter region and a 3 kbp promoter region. The most recent results suggest 
that there might be an unidentified upstream activating element allowing 
activation of the amylase I gene. The hypothesis for my work was that 
transfecting amylase I promoter clones containing different promoter regions in 
different cell types will activate the promoter region. Mouse and rat amylase I 
promoter clones were made containing a 1 kbp proximal promoter region, and 
one clone was made containing both the 1 kbp proximal promoter region and a 2 
kbp region about 2.5 kbp upstream of the proximal promoter region of both the 
mouse and rat amylase 1 gene. Sequence analysis of the mouse 1 kbp promoter 
region identified transcriptional repressor binding sites. A 900 bp and a 700 bp 
promoter clone were made with these sites removed. The promoter fragments 
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were ligated into a luciferase reporter vector. The promoter clones were tested 
for promoter activity by transient transfection studies, and were transfected in 
three different cell types. The rat amylase promoter clones were transfected in a 
parotid acinar cell type. Amylase promoter activity was measured by performing 
assays that measured firefly luciferase expression, and transfection efficiency 
was measured by performing assays measuring renilla luciferase expression. 
The promoter activity was determined by normalizing firefly luciferase RLU 
values to renilla luciferase RLU values. 
 
NUPR1 GENE 
 NUPR1, nuclear protein 1, or p8, was first discovered as a gene activated 
in the acute phase of pancreatitis [38]. It has been shown to have increased 
levels in developing pancreas and liver [39]. Screening of human pancreatic 
cDNA library characterized the NUPR1 gene as having three exons and two 
introns with 5’ and 3’ untranslated regions, and the gene is located on 
chromosome 16 [40]. The NUPR1 protein has a bipartite signal for nuclear 
localization suggesting it functions in the nucleus. It also contains a basic helix-
turn-helix motif that allows the protein to bind DNA as a transcription factor [38-
40]. Mallo et. al. performed northern blot analysis to analyze NUPR1 mRNA [39]. 
They found NUPR1 was highly expressed in salivary glands and expressed to a 
lesser extent in stomach, colon, liver, and kidneys. The brain, spleen, testes, 
thymus, and skeletal muscles all had an absence of NUPR1 mRNA. Tissues 
expressing NUPR1 only express this gene in exocrine cells [39]. The NUPR1 
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gene has been further characterized by parotid gland mRNA analysis as well as 
data showing high NUPR1 expression in salivary glands, localization of 
expression in acinar cells. 
NUPR1 gene expression has not been characterized in parotid gland 
differentiation. NUPR1 mRNA had elevated expression in the analysis of 
transcription factors involved in parotid gland differentiation. Transcription factors 
that increased in expression at the same time as NUPR1 were tested as possible 
activators of NUPR1 gene expression. These transcription factors included 
Cited2 and IRF-2. A detailed explanation of these transcription factors and the 
co-factors p300 and PCAF are described in following sections. The hypothesis 
for this section of the research was that NUPR1 promoter activity would increase 
when a Cited2/p300 combination or an IRF-2/PCAF combination is co-
transfected. The cDNA combinations and the NUPR1 promoter driving luciferase 
were transiently expressed in ParC10 and 3T3-L1 cells to determine promoter 
activity.  
 
PAROTID SECRETORY PROTEIN 
 Parotid secretory protein (PSP) was first identified as a leucine-rich protein 
in rat saliva samples, and was later found as a major protein component of 
mouse saliva [41]. PSP is found located on mouse chromosome two and on rat 
chromosome three. Murine PSP is first detected in embryonic terminal clusters 
and lumina, and the levels continue to increase throughout development, 
reaching high levels in the adult gland [14]. PSP is an abundant product of 
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mouse parotid acinar cells, and is found in low levels in sublingual serous cells 
[4]. The mRNA levels of PSP in parotid acinar cells is about 10% of the total 
cellular mRNA and about ten fold lower in sublingual glands [4, 42]. Poulsen et. 
al. performed northern blot analysis of mouse tissue and quantified PSP mRNA 
expression in various tissues [30]. They found the mouse parotid gland had the 
most abundant PSP mRNA, with lesser amounts found in submandibular and 
sublingual glands, even lower amounts in the pancreas, and undetectable 
amounts in the liver. Another finding from this experiment was that the tissue 
specific expression of mouse PSP parallels levels of mouse amylase expression. 
The conclusion from this data is that PSP and amylase are expressed in the 
mouse parotid gland. In humans, PSP mRNA expression is found in the 
submandibular and parotid glands [43].  
PSP belongs to the PLUNC (palate, lung, and nasal epithelium clone) 
protein family, which consists of mucosal secretory proteins [44]. Specifically, 
rodent PSP is the orthologue of the human PLUNC protein, SPLUNC2 [45]. 
PLUNC proteins are related to the BPI/LBP/CTEP lipid-binding protein family. 
Bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide binding 
protein (LBP) bind lipopolysaccharide (LPS) constituents of bacterial cells walls 
on Gram-negative bacteria, lipoteichoic acids of Gram-positive bacteria, and 
lipoarabinomannas of mycobacteria [46]. LPS receptors of macrophages and 
neutrophils recognize LPS bound to BPI or LBP and result in a cellular response 
that destroys the invading pathogen or renders the pathogen inactive [43]. Since 
PSP, PLUNC, and BPI/LBP proteins are related, it has been suggested that PSP 
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may function similarly to the BPI/LBP proteins. These predicted functions include 
binding to bacteria and having an antibacterial effect, having growth-suppression 
effects on bacteria, promoting anti-inflammatory effects, and causing bacterial 
agglutination [45]. Gorr et. al. expressed PSP in the rat cell line GH4C1 to test 
PSP antibacterial activity [47]. Their data resulted in reduced colony numbers of 
Pseudomonas aeruginosa supporting evidence for PSP bactericidal activity, and 
they also observed reduced E. coli colony numbers presumably due to PSP 
enhancing bacterial agglutination. This data support the idea of PSP being 
antibacterial and helping agglutinate bacteria.  
Nothing is known about the characterization of the PSP gene. A significant 
goal of this work is to determine transcription factors that enhance PSP promoter 
activity. Mist1 was a transcription factor predicted in the hypothetical network to 
activate the PSP gene. The hypothesis was that Mist1 transcription factor or a 
Mist1/Tcf3 transcription factor combination will activate the PSP promoter. The 
goals of PSP promoter experiments were to determine if Mist1 activates the PSP 
promoter, and to determine if mutating Mist1 DNA binding sites, or E-box 
sequences (described in the following sections), will prevent PSP promoter 
activation. Another goal of testing PSP gene activation was to test the affect of 
Mist1 on other locations of the PSP gene. One group found that Mist1 activated 
the Mindbomb 1 gene (Mib1) through the first intron [48]. E-box binding sites 
were found in the second and third introns of the PSP gene. This region was 
ligated into a PSP promoter-luciferase clone, and transient transfection studies 
were performed to test Mist1’s affect on the PSP promoter + intron clone. The 
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next goal was to co-transfect the E-protein, Tcf3, with Mist1 to see the 
combinatorial effect of the transcription factors on the PSP promoter and PSP 
promoter + intron.  
 
CITED2 AND P300 TRANSCRIPTIONAL CO-ACTIVATORS 
 In the hypothetical transcription factor network, Cited2 was predicted to 
activate NUPR1 gene expression. Cited2 belongs to a family of genes known as 
CITED (cAMP response element binding protein (CBP)/p300 interacting 
transactivators with ED-rich termini) [49, 50]. These proteins do not bind DNA, 
but serve as transcriptional co-activators. Cellular Cited2 binds tightly to the 
CBP/p300 transcription complex, and in turn the CBP/p300 complex binds to 
DNA bound transcription factors to facilitate RNA polymerase II gene 
transcription [51]. Interaction of Cited2 protein with CBP/p300 regulates 
pathways influenced by this transcription complex such as co-activation of the 
transcription factor AP2 [49]. Cited2 protein is involved in organogenesis, and the 
early stages of adrenal tissue growth and adrenal differentiation [50, 52]. Also, 
studies performed by Bamforth et. al. used Cited2 null mouse embryos to 
determine how the absence of Cited2 caused complications in cardiac, neural 
crest, and neural tube development [53]. They used in vitro binding assays and 
found the C-terminal end of Cited2 interacts with the transcription factor Tfap2, a 
factor involved in neural crest and neural tube development. To confirm Cited2 
enhances target gene transcription by Tfap2, transient transfection studies found 
that the activity of a luciferase reporter vector containing Tfap2 binding elements 
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increased when Tfap2 and Cited2 were co-expressed, as compared to 
expression of Tfap2 alone. These experiments confirmed that Cited2 is required 
for proper development of the neural crest.  
 The nuclear phosphoproteins, p300 and cAMP response element binding 
protein (CBP), are homologous and widely expressed [54, 55]. p300 is a co-
activator that links DNA-bound transcriptional activators to the basal transcription 
machinery. It has histone acetyltransferase (HAT) activity that is involved in 
modifying chromatin structure within gene promoters, and the HAT activity also 
allows p300 to increase DNA binding efficiency of p300-interacting transcription 
factors [56, 57]. Both of these histone modifying actions result in more efficient 
transcription of target genes. One example of p300 enhancing transcriptional 
activity of skeletal muscle specific genes is by acetylating the transactivation 
domain of myocyte enhancer factor 2 (MEF2) to increase its DNA binding ability 
[56]. Also, nuclear hormone receptors like the thyroid hormone receptor have 
enhanced transcriptional activity in the presence of p300 [58]. The bHLH skeletal 
muscle transcription factor, MyoD, requires p300 to fully activate gene promoter 
targets [57, 59-61]. These examples of p300 helping activate transcriptional 
activation support the co-expression of p300 with Cited2 in the experiments 
performed in the research described in this thesis.   
 Cited2 was of interest in the following research because its mRNA levels 
increased about the same time as NUPR1 mRNA levels during parotid 
development. The co-activator, p300, was of interest because it has been cited 
numerous times in the literature as having interactions with Cited2 to enhance 
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gene activation. The hypothesis was that a combination of Cited2/p300 would 
increase NUPR1 promoter activity. Transient transfection experiments in ParC10 
and 3T3-L1 cell types were performed to test the effect of the Cited2/p300 
combination on NUPR1 activity.   
 
IRF2 TRANSCRIPTION FACTOR AND PCAF CO-FACTOR 
 IRF2 belongs to the interferon regulatory (IRF) transcription factor family. 
This transcription factor shares sequence homology to the IRF-1 gene in the 5’ 
half of the protein coding region [62]. IRF2 is a nuclear factor that binds various 
DNA elements. One of these elements in called IRF-E and the consensus 
sequence is G(A)AAAG/CT/CGAAAG/CT/C [63]. Another sequence IRF-2 binds 
is the interferon consensus sequence (ICS), also know as the interferon 
stimulated response element (ISRE), and the DNA binding sequence for this 
element is A/GNGAAANNGAAACT [64, 65]. One last element IRF-2 binds is 
known as the positive regulatory domain I (PRDI) of the IFN-" gene [66].  
 IRF-2 is a very stable protein with an eight-hour half-life [67]. The C-
terminal domain of IRF-2 is rich in basic amino acids and contains a repression 
domain [65]. The DNA binding activity is found in the N-terminal domain and 
consists of three !-helices, four-stranded antiparallel "-sheets, and three long 
loops [62]. This structure is similar to the binding domain of bHLH proteins 
(described in a later section), however, the DNA interaction between these two 
protein families differ [68]. The third !-helix of IRF-2 binds the major groove 
containing the GAAA portion of the IRF-E or ICS binding sites while the other 
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binding domain segments interact with the surrounding sequence. 
Phosphorylation by protein kinase A (PKA), protein kinase C (PKC), and casein 
kinase II (CK2) at multiple serine sites affect IRF-2 regulation during cell growth 
[69].    
IRF-2 can act as a transcriptional repressor or a transcriptional activator. 
Proteolytic cleavage of IRF-2 is induced by interferons, viral infection, or dsRNA 
treatment and becomes a transcriptional activator or repressor [65]. Once IRF2 is 
efficiently expressed it represses interferon-stimulated response elements in 
other genes induced by the interferon stimulus, such as IRF-1 [70]. Hamada et. 
al. performed transfection experiments comparing the effects of IRF-1 and IRF-2 
on IFN-" promoter expression in cell culture [62]. This promoter was activated by 
IRF-1 alone, repressed by IRF-2 alone, and when there was co-expression of 
IRF-1 and IRF-2 the promoter was repressed. The conclusion from this 
experiment was that IRF-2 silences IRF-1. Genes that are activated by IRF-2 are 
the vascular cell adhesion molecule-1 (VACM-1) gene, and the human H4 
histone gene [71, 72]. Jesse et. al. observed the activation of the VCAM-1 gene 
by IRF-2 in the IRF-E sequence of the gene promoter. Their data indicated that 
the basic repression domain in the COOH-terminal end was inactive in 
myoblasts, and that an acidic latent activation domain resides in the central 
region of the protein. IRF-2 is also involved in cell cycle growth control and cell 
cycle progression as a transcriptional activator of the human H4 histone gene, 
FO108 [69].  
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The transcriptional cofactor p300/CBP-associated factor (PCAF) is mainly 
located in the nucleus and has histone acetyltransferase (HAT) activity [73-75]. 
The acetylation occurs post-translationally on the N#-amino-group of a lysine 
residue [76]. These modifications influence protein functions such as protein-
protein interactions, protein association with DNA, and protein stability. PCAF is 
a subunit of the SAGA-type multi-protein complex that functions as a co-activator 
of transcription. Transcription is stimulated by the acetyltransferase activity of the 
complex leading to modification of nucleosomes through interaction with 
nucleosome remodeling enzymes.  
PCAF has numerous targets that regulate different pathways in the body. 
A few proteins that PCAF targets are tumor suppressors, and modification of 
these proteins decreases cell growth [73]. The tumor suppressor p53 is 
acetylated and activated upon DNA damage by PCAF to slow down cell growth 
and promote apoptosis [77]. Other proteins involved in tumor suppression are 
p73, which functions similarly to p53, and Bax proteins that mediate apoptosis 
[74, 78]. Contrary to these tumor suppressor targets, PCAF also activates tumor 
activator protein c-Myc by increasing its stability, which could be one cause of its 
characteristic overexpression in cancer [79]. Acetylation of the tumor suppressor 
protein PTEN decreases its potential to inhibit cell cycle progression [80]. An 
instance where PCAF is required as an activator in non-cancer associated 
context is by enhancing the activity of the estrogen receptor, the glucocorticoid 
receptor, and the androgen receptor when the appropriate ligand for these 
receptors is present [81]. PCAF has been shown to be required for progestin 
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induction of target genes [75]. Also, PCAF acetylates and activates the 
retinoblastoma protein to promote differentiation and to keep this protein 
localized to the nucleus [82].   
IRF-2 has been shown to recruit PCAF in order to enhance its own binding 
to the ISRE [83]. DNA affinity binding assays and immunoblot assay performed 
by Masumi et. al. found that IRF-2 directly binds PCAF in order to bind the ISRE. 
Assays testing the enzymatic activity of PCAF on the ISRE-IRF-2 complex found 
PCAF is a major contributor to acetylation in this complex. This group also found 
that PCAF binds the internal DNA-binding domain of IRF-2 using C-terminal 
truncations of IRF-2. The C-terminal domain of PCAF contains the histone 
acetylase catalytic domain and a bromodomain, and in vitro experiments support 
that the bromodomain of PCAF is where IRF-2 binds. IRF-2 has been shown to 
activate the H4 gene, so Masumi et. al. ligated the H4 ISRE binding site to a 
luciferase reporter vector to test promoter activation from IRF-2 and PCAF. The 
combination of IRF-2 and PCAF yielded higher luciferase activity than IRF-2 
alone indicating that PCAF is a co-activator for IRF-2.  
In this thesis, the IRF-2 transcription factor was studied to determine its 
effect on the NUPR1 promoter. The mRNA analysis of transcription factors 
involved in parotid gland differentiation showed that IRF-2 is at elevated levels as 
NUPR1 levels increase. This IRF-2 mRNA analysis and the study showing that 
IRF-2 and PCAF interact and enhance promoter activation led to the decision to 
co-express this transcription factor and co-activator with the NUPR1 promoter. 
The hypothesis was that a combination of IRF-2/PCAF would increase NUPR1 
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promoter activity. This was accomplished by performing transient transfection 
experiments co-expressing NUPR1 promoter driving luciferase, and the IRF-
2/PCAF combination in 3T3-L1 cells.  
   
MIST1 TRANSCRIPTION FACTOR 
 Mist1 belongs to the basic helix-loop-helix (bHLH) transcription factor 
family, specifically class II bHLH proteins [84, 85]. The bHLH protein family is 
large and has been organized into different classes (I-VII), each class referring to 
their tissue expression, DNA-binding abilities, and dimerization properties. These 
proteins are widely expressed in tissues, form homodimers or heterodimers with 
other bHLH family members, and bind exclusively to E-box consensus sites [85, 
86]. The bHLH-motif contains two amphipathic !-helices separated by a variable 
loop region with a basic region that binds DNA [84]. Dimerization of bHLH 
transcription factors allows the basic domains to interact and bind the E-box DNA 
sequence, -CANNTG-, to promote activation of most genes [86-88]. Dimers of 
bHLH proteins will line up with the E-box DNA sequence so one monomer 
interacts with one half-site, CAN, and the other monomer interacts with the NTG 
half-site [85]. Evidence has determined bHLH transcription factors can be “tissue-
specific” or “ubiquitous”, and family members will have differential expression 
during development.  
 Mist1 shares the same bHLH-motif as other bHLH family members, but 
has a unique C- and N-terminal domain [84]. The N-terminal domain (repressor 
domain) has been shown to negatively regulate bHLH-mediated transcription 
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[89]. Translocation to the nucleus and formation of homodimers and 
heterodimers with E-proteins allows Mist1 to bind E-box consensus DNA binding 
sites and activate or repress gene expression depending on cellular contexts [84, 
90].  
 Mist1 expression has been found in different species such as mouse, rat, 
human, and zebrafish [90]. Pin et. al. used a “knock-out” mouse model by 
replacing a coding region of the Mist1 locus with the bacterial LacZ gene to follow 
Mist1 mRNA expression and to identify cells that accumulate Mist1 protein [91]. 
This model was used to create a Mist1-LacZ mouse line. Tissues from these 
mice were stained for "-galactosidase (LacZ) to measure levels of Mist1 mRNA 
expression is different tissues. LacZ expression indicated Mist1 positive tissues. 
Assays testing Mist1-LacZ mice measured about a 1000-fold increase in LacZ 
expression in pancreatic and salivary gland tissues compared to Mist1 negative 
kidney tissue. Mist1 is present in pancreas, parotid gland, submandibular gland, 
small intestine, male reproductive tract, and stomach secretory cells (mucus-
secreting cells, parietal cells, and chief cells) because LacZ was also expressed. 
Mist1 specific polyclonal antibodies were used to examine protein expression in 
cells. Mist1 was found located specifically in exocrine cells throughout the body 
with high levels found in pancreatic acinar cells and in salivary glands; 
specifically in serous cells of the parotid gland and seromucous type cells in the 
submandibular gland. Cells in the sublingual gland, ductal cells, and endocrine 
cells were negative for Mist1. Based on work by other groups, other tissues 
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found to express Mist1 are chief cells in the stomach, mammary glands, seminal 
vesicles, and lacrimal glands [90, 92]. 
 Mist1 knockout studies have suggested Mist1 as a regulator of acinar cell 
polarity and secretory granule formation. Calcium signaling complexes were 
observed in acinar cells of Mist1 null mice [93]. Calcium signaling is polarized 
from the apical-to-basal end of exocrine secretory cells and the localization of the 
calcium signaling complexes and intracellular organelles are important for proper 
calcium signaling. Digestive enzyme secretion in the pancreas is activated by 
calcium, and disruption of the calcium signaling of this process has been shown 
in acute pancreatitis. Mist1 is required for the normal development of serous 
acinar cells in the pancreas and salivary glands. Mist1 knockout acinar cells have 
altered calcium signaling due to the mislocalization and aberrant calcium uptake 
by the mitochondria, which is a key player in controlling the calcium wave from 
the apical-to-basal end of the cell. The digestive enzyme content in Mist1 null 
cells is about 2.5 to 3-fold less in amylase, trypsin, and lipase as compared to 
wildtype cells, which may be due to a diffuse and fragmented Golgi apparatus. 
Changing calcium levels in a functioning cell are a major stimulator of exocytosis 
in pancreatic acini. Stimulated amylase secretion was measured to quantify 
exocytosis and found that exocytosis was impaired in the Mist1 knockout acinar 
cells. This result suggested that the lack of exocytosis is due to secretory 
granules are being mislocated and the calcium signaling complexes were 
impaired. The study findings just described suggest Mist1 is involved in 
controlling the localization and integrity of mitochondria and the Golgi apparatus 
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and it controls the localization of secretory granules. The findings further support 
the importance of Mist1 in correct acinar cell formation with properly localized 
intracellular organelles involved in the apical-to-basal calcium oscillations and 
waves important to cell function. 
 Another use of the Mist1 null mice model was studying the effect Mist1 
has on Ras-like small GTPases, such as RAB3D and RAB26, that regulate 
vesicular formation and transport [94]. A chief cell type was studied, the 
zymogenic cell lineage (ZC), which is a cell located in the base of the gastric unit. 
Mist1 expression has been shown to begin in easrly stages of ZC differentiation 
and is involved in the formation and maintenance of secretory granules and 
apical-basal reorganization. Mist1 null ZC’s were observed to have smaller 
zymogen-containing vesicles and defects in the apical-to-basal organization. 
Granules are usually found predominately in the apical end of the cell, but the 
granules in Mist1 null cells were equally distributed in the apical and basal ends. 
Inappropriate granule trafficking resulted at the basal end, and the nucleus was 
localized at the apical end. The proteins RAB3D and RAB26 are involved in large 
granule formation in the gastric epithelial cells. Mist1 was shown to directly bind 
these RAB proteins in vitro by ChIP analysis on a cell line stably expression 
Mist1-eGFP. In situ hybridization found RAB3D and RAB26 expression is 
confined to Mist1 expressing ZCs in wildtpye mice, and laser-capture 
microdissection (LCM) determined that Mist1 null ZCs had barely detectable 
levels of RAB26 as compared to background levels, and the RAB3D expression 
was significantly decreased. These in vivo experiments confirmed that Mist1 
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transcriptionally regulates these RABs. These experiments further suggest Mist1 
is important to proper secretory granule formation and for proper organelle 
localization.           
 The majority of information on parotid secretory protein (PSP) focuses on 
the protein functions in saliva, but there is not as much information on gene 
expression of PSP gene. The PSP proximal promoter region has not been 
characterized. Previous analysis of rat parotid mRNA showed patterns of 
transcription factors involved in parotid gland differentiation. Mist1 was a 
transcription factor that had elevated levels as PSP was being expressed. Also, 
Mist1 DNA binding sites, or E-box sites, were found upon analysis of the PSP 
promoter sequence. This led to my hypothesis that Mist1 would activate the PSP 
promoter. The specific aims focusing on proving this hypothesis were to 
determine if Mist1 activates the PSP proximal promoter, and to determine if 
mutating E-box sites would prevent Mist1 activation. Transient transfection 
studies co-expressing rat Mist1 cDNA with rat PSP promoter DNA were used to 
accomplish these goals.  
  
E2A (Tcf3) TRANSCRIPTION FACTOR 
 E2A belongs to the class I bHLH and the E-protein family [86]. The E2A 
gene, also referred to as Tcf3, encodes two class I bHLH transcription factors, 
E12 and E47, and the isoforms have been shown to form a heterodimer with 
Mist1 transcription factor [84-86, 95]. The bHLH-motif of E12 and E47 have 
conserved residues sharing sequence homology with the Drosophila proteins 
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Daughterless, MyoD, and the Myc transcription factor family [85]. The HLH motif 
provides a dimerization domain of two amphipathic !-helices separated by a 
flexible loop [85]. The E47 dimer forms a four-helix bundle which allows the basic 
region of the bHLH-motif to contact the major groove of DNA as loop residues 
and one of the helices contacts DNA surrounding that region [96].  E2A binds E-
box consensus sequences, and this site promotes cell-specific gene expression 
by regulating promoter and enhancer regions for specific gene expression in 
muscle, pancreatic, and neuronal cells [85]. This transcription factor is widely 
expressed in tissues and can act as a transcriptional activator or repressor 
depending on its binding partner and other co-activators or co-repressors [86].  
  There are many functions of E2A transcription factor. E2A is essential for 
B-cell development and activates genes involved in this process [85, 88, 95]. The 
two proteins encoded by the E2A gene, E12 and E47, are essential for the 
progression of early B cells past the very early progenitor stage [95]. The murine 
mb-1 promoter was studied to understand the control for tissue and 
differentiation stage-specific transcription in B cell development. E2A isoforms 
have been shown to bind E-box sequences in this promoter and are required for 
its activation. Genes specific to pancreatic development contain E-box 
sequences and require the heterodimer formation of E2A and the class II bHLH 
BETA2 for pancreatic differentiation [85]. One E2A function that has been 
suggested is its role in tumor suppression [97]. Mice that were deficient in E2A 
rapidly developed T-cell lymphomas and loss of E2A homodimers appeared to 
have a role in T-cell leukemia development. The ectopic expression of E2A in 
$$"
mice lacking this transcription factor induced apoptosis and therefore supports its 
role in tumor suppression. Another way E2A enhances gene activation is by 
interacting with cofactors such as p300, CBP, and PCAF in the AD1 and AD2 
activation domains in the N-terminal [88, 98]. Both the E12 and E47 proteins 
have been shown to recruit p300, a co-activator with histone acetyltransferase 
activity involved in chromatin remodeling, and this interaction enhances 
transcriptional activity [98]. 
There are also instances of repression by E2A isoforms. The E12/E47 
heterodimer have been shown to repress activity on cell-cell adhesion protein E-
cadherin during epithelial-mesenchymal-transition (EMT) of embryonic tissue 
development and of metastases [86, 88, 99]. Also, binding with the class V bHLH 
protein, Id, negatively regulates E-protein transcriptional activity. Id proteins lack 
the basic domain that would bind DNA in target promoters, and this blocks the 
transcriptional activity of the bound E-protein [100].  
Mist1 transcription factor alone repressed PSP promoter activity. Tcf3 
transcription factor was utilized as a binding partner for Mist1 in experiments 
testing the activity of PSP promoter and PSP promoter + intron activity. The 
hypothesis was that co-transfection of Mist1 and Tcf3 would increase PSP 
promoter and/or PSP promoter + intron activity. The goals were to determine how 
the PSP promoter and the PSP promoter + intron clones were affected by the 
Mist1/Tcf3 combination, and to determine the specific effects of Mist1, Tcf3, and 
the Mist1/Tcf3 combination. This was accomplished by transfecting ParC10 cells 
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and transiently expressing rat Mist1 and rat Tcf3 cDNA with rat PSP promoter or 










AMYLASE-1 PROMOTER CLONES  
 Different amylase 1 (Amy1a) promoter clones were made using the PCR 
amplification method. The promoter regions were determined using the ECR 
Browser: Evolutionary Conservation of Genomes website, 
http://ecrbrowser.dcode.org/. The rat and mouse Amy1a promoter regions were 
compared on ECR. Conserved regions containing suggested activating 
transcription factor binding sites were chosen. A 1000 base pair region (mAmyI 1 
kb) spanning the proximal promoter, and an adjacent 2000 base pair region 
(mAmyI R2) were mapped (Figure 1). These regions were cloned into an empty 
pGL4.10 luciferase vector supplied by Promega. This vector produces luciferase 
protein that can be used as a measure of promoter activity. Primers flanking the 
mouse promoter regions of interest were designed for PCR amplification and are 
listed in Table 1. The forward primer for the 1000 base pair promoter region, 
termed ‘M.Amy1 1kb BglII For’, contains a BglII restriction site, and the reverse 
primer for this region, ‘M.Amy1 1kb HindIII Rev’, contains a HindIII restriction site. 
The forward primer for the 2000 base pair promoter region, ‘M.Amy1 XhoI R2 
For’, contains a XhoI restriction site, and the reverse primer for this region, 
‘M.Amy1 BglII Rev’, contains a BglII restriction site. PCR amplification of mAmyI 
1kb and mAmyI R2 started with an initial denaturation of mouse genomic DNA at 
95 °C for 6:00. This was followed by eight cycles of denaturation at 95 °C for 
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thirty seconds, annealing at 58 °C for thirty seconds, and extension at 72 °C for 
two minutes. These eight cycles were followed by twenty-five cycles of 
denaturing at 95 °C for thirty seconds, then annealing at 60 °C for thirty seconds, 
and extension at 72 °C for two minutes and ten seconds. The PCR products 
were purified by spinning down PCR reactions onto a silica membrane using the 
QIAquick PCR Purification Kit (Qiagen) according to the spin protocol. After 
being purified, mAmyI 1kb PCR product and an empty pGL4.10 luciferase vector 
were double digested with BglII and HindIII restriction enzymes creating fragment 
ends that hybridized together during a ligation reaction. The mAmyI R2 PCR 
product and an empty pGL4.10 luciferase vector were double digested with BglII 
and XhoI restriction enzymes. The digested promoter fragments and pGL4.10 
vectors were purified via gel extraction according to the QIAquick Gel Extraction 
Kit spin protocol. After quantitating the DNA obtained from the gel extraction, 
mAmyI 1kb was ligated into pGL4.10 digested with BglII and HindIII, and mAmyI 
R2 was ligated into pGL4.10 digested with BglII and XhoI using T4 DNA ligase 
supplied by Invitrogen. The samples were put in a PCR Thermocycler overnight 
at 16 °C. The ligation reactions were transformed into TOPO 10 DH5-! 
competent cells. Colonies were screened for promoter inserts using the Promega 
Wizard Plus SV Minipreps DNA Purification System by lysing the cells, removing 
endonucleases and other proteins released during lysis using an alkaline 
protease, neutralizing the lysate, and then applying the neutralized lysate to a 
spin column membrane. Once miniprep DNA was quantified, these clones were 
screened by restriction enzyme digests. A double digest using enzymes BglII and 
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HindIII were used to determine miniprep samples containing mAmyI 1kb inserts. 
The enzyme BsaI was used to screen for the promoter fragment in the mAmyI R2 
miniprep samples. Samples containing correct fragment lengths on a 1% 
agarose gel were confirmed by sequencing.  
These single promoter fragment clones were then combined to include 
both promoter fragments in order to test if promoter expression was stronger with 
the regions together. The promoter fragment, mAmyI R2, was ligated into the 
mAmyI-1kb-pGL4.10 clone. First, the R2 region was amplified using the same 
PCR primers listed in Table 1 for the R2 region and the same PCR conditions 
listed above. After the PCR product was purified, the R2 fragment and mAmyI-
1kb-pGL4.10 DNA was double digested with XhoI and BglII restriction enzymes. 
The mAmyI R2 fragment and mAmyI-1kb-pGL4.10 DNA was purified via gel 
extraction and then ligated together with T4 DNA ligase. The mAmyI-R1-
R2.pGL4.10 ligation product was transformed into TOPO 10 DH5-! competent 
cells. Colonies were chosen and screened for the correct promoter insert using 
the Promega Wizard Plus SV Minipreps DNA Purification System. The miniprep 
samples were digested with SacI enzyme to screen for a clone with the inserted 
mAmyI R2 region. Samples containing the correctly digested band lengths were 
confirmed by DNA sequencing. 
The 1000 base pair amylase promoter sequence was analyzed for 
transcriptional repressor binding sites. Promoter clones with these sites removed 
were cloned into a Promega pGL4.23 luciferase vector. This vector contains a 
minimal promoter to enhance the DNA region of interest expression. The two 
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promoter regions were 900 base pairs and 700 base pairs in length and 
designated mAmy1-900bp and mAmy1-700 bp. The forward primer used for both 
was the same primer used for amplifying the 1000 base pair promoter region. 
The reverse primer used for mAmy1-900bp promoter region was mAmy1 900bp 
HindIII Rev that contains a HindIII restriction site. The reverse primer for mAmy1-
700bp promoter region was mAmy1 700bp HindIII Rev also containing a HindIII 
restriction site. These three primers are listed in Table 1. The PCR conditions 
used to amplify the promoter regions consisted of an initial denaturation at 95 °C 
for six minutes followed by eight cycles of denaturation at 95 °C for thirty 
seconds, annealing at 55 °C for thirty seconds, and extension at 72 °C for two 
minutes. These cycles were followed by twenty-five additional cycles of 
denaturation at 95 °C for thirty seconds, annealing at 58 °C for thirty seconds, 
and extension at 72 °C for two minutes. The PCR products were purified via the 
QIAquick PCR Purification Kit following included instructions. Both the 900 base 
pair and 700 base pair PCR products and a pGL4.23 luciferase vector were 
digested with BglII and HindIII restriction enzymes. The digested promoter 
fragments and the digested pGL4.23 luciferase were gel purified using the 
QIAquick Gel Extraction kit. After purification, an overnight ligation reaction using 
T4 DNA ligase was performed at 16 °C in order to ligate the 900 base pair and 
700 base pair promoter fragments into the pGL4.23 vector. The ligation products 
were transformed into TOPO 10 DH5-! competent cells. Colonies were grown up 
and screened for promoter inserts using the Promega Wizard Plus SV Minipreps 
DNA Purification System. After the DNA was quantified, mAmy1-900bp promoter 
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inserts were screened by a BssSI restriction digest, and mAmy1-700bp promoter 
inserts were screened by a double digest using NotI and BglII restriction 
enzymes. The digested DNA was analyzed via gel electrophoresis, and samples 
with correct band lengths were sent to sequence at the University of Louisville 
DNA sequencing core. Correct promoter sequences were confirmed and these 
DNA samples were purified using the QIAfilter Plasmid Midi Prep kit. This DNA 
purification is a modified alkaline lysis procedure where the neutralized lysate is 
bound to a QIAGEN Anion-Exchange Resin. After the lysate is applied to the 
resin, impurities such as RNA are removed by a medium-salt wash, and then an 
elution with a high-salt buffer concentrates plasmid DNA. The DNA is desalted by 
isopropanol precipitation.  
The NUPR1 promoter region was amplified by PCR and ligated into the 
pGL4.10 luciferase vector by standard cloning methods as described above. 











Table 1: PCR primers for mouse Amylase 1 promoter clones 
Clone  PCR primer used Tm 
R1 
Forward:  


















5'-CACCAGATCTCTCAGCTTCAGCATCACATCTCTG-3'                                    
Reverse:  
5'-CACCAAGCTTTCTTGGGGGAAAAGGAGTTT-3'      
For: 



























E-BOX MUTANT PSP PROMOTER CLONES 
 The PSP 2000 base-pair promoter sequence and the pGL4.10 luciferase 
vector sequence were analyzed for Mist1 transcription factor binding sites, or an 
E-box consensus sequence binding site, 5’-CANNTG-3’ [85]. Two sites were 
found in the PSP 2kb promoter region, and three sites were found in the pGL4.10 
vector. Mist1 transcription factor was predicted to enhance expression of PSP. E-
box sites were mutated in a previously made clone containing the PSP 2kb 
promoter region ligated into pGL4.10.  
 First, to eliminate any background activity from Mist1 the sites in the 
pGL4.10 vector were mutated. The sites mutated in pGL4.10 were designated 
site A, site B, and site C and are depicted in Figure 11. The mutagenic primers 
used are listed in Table 2 below. The QuikChange II Site-Directed Mutagenesis 
Kit supplied by Agilent Technologies was used to perform mutagenesis of the 
Mist1 sites according to kit instructions. First site A was mutated, and then this 
confirmed clone was used as a template to mutate site B resulting in a clone that 
had both sites A and B mutated. Then this double Mist1 mutant clone was used 
as a template for mutating Mist1 site C. The final product was pGL4.10 with Mist1 
binding sites A, B, and C mutated termed, ‘Mist1mut-ABCpGL4.10’. The PCR 
conditions used for all mutations were an initial denaturation of 95 °C for thirty 
seconds, followed by sixteen cycles of denaturation at 95 °C for thirty seconds, 
annealing at a temperature specific for the mutagenic primer used for one 
minute, and extension at 68 °C for five minutes. After the PCR reaction, PCR 
products were digested with DpnI enzyme. DpnI enzyme digested parental DNA 
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that was not mutated during the PCR reaction. The digested product was 
transformed into TOPO 10 DH5!-T1 competent cells and plated on ampicillin 
agar plates. Colonies were chosen, inoculated in LB broth, and grown in order to 
screen them for correct mutations. The Promega Wizard Plus SV Minipreps DNA 
Purification System was used to extract DNA from the bacterial cells, the DNA 
was quantified, and then sent for sequencing. Confirmed sequences with 
correctly mutated binding sites were purified using the QIAfilter Plasmid Midi 
Prep Kit via kit instructions. 
 The next step was to ligate the PSP 2kb promoter region into the mutated 
pGL4.10 vector. The PSP 2kb promoter clone previously made in the laboratory,                  
-1980PSPprom.pGL4.10, and the mutated pGL4.10 was digested with KpnI and 
XhoI restriction enzymes. The digested fragment and vector were gel purified 
using the QIAquick Gel Extraction kit. The purified PSP 2kb promoter was ligated 
into the purified, mutated pGL4.10 using T4 DNA ligase at 16 °C overnight. The 
ligation product was transformed into TOPO 10 DH5-! competent cells. Colonies 
were inoculated and screened for the promoter insert using the Promega Wizard 
Plus SV Minipreps DNA Purification System followed by XhoI digest to screen for 
the correct insert. Samples containing correctly digested band lengths were sent 
to sequence. The correct sequence was confirmed and the plasmid clone purified 





Table 2: Mutagenesis primers for Mist1 mutant pGL4.10 and rat PSP 2kb 











































































PSP PROMOTER + INTRON CLONES  
 The PSP 2kb promoter clone and the E-box mutant PSP 2kb promoter 
clones were repressed by Mist1 transcription factor. Therefore, additional sites in 
the PSP gene by which Mist1 could activate transcription were sought. There is 
evidence that Mist1 binds E-box sequences within the first intron of genes, such 
as the ubiquitin ligase Mindbomb1, Mib1, gene [48]. The intron regions of the 
PSP gene were analyzed for Mist1 E-box binding sites, and sites were found 
within the second, third, and fifth introns. PCR primers were made for the regions 
between the second and fourth exons and between the second and sixth exons, 
but the region between the second and fourth exons was the only region 
successfully amplified. This region will be referred to as the PSP intron region. 
The PCR primers used to clone the intron region were: the forward primer with a 
SalI restriction site, PSPex2SalI For B: 5’ –CAA CTT GTC GAC CTT GTG GTC 
TTG TGT GGC-3'; the reverse primer with a SalI restriction site, PSPex4SalI 
Rev: 5'-CAT TGG TCG ACA GCC CAG CTT GAA GAT CC-3'. The PCR 
conditions used to amplify the PSP intron region consisted of an initial 
denaturation at 95 °C for six minutes, followed by eight cycles of denaturation at 
95 °C for thirty seconds, annealing at 61 °C for thirty seconds, and extension at 
72 °C for two minutes and twenty seconds. After these eight cycles, the reaction 
underwent twenty-five more cycles of denaturation at 95 °C for thirty seconds, 
annealing at 63 °C for thirty seconds, and extension at 72 °C for two minutes and 
thirty seconds. Then the amplified intron region was PCR purified using the 
QIAquick PCR Purification Kit following the kit instructions.  
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 The next step was to insert the amplified intron region into the PSP 1.5 kb 
promoter construct made previously in the laboratory. The PSP 1.5 kb promoter 
was digested with XhoI restriction enzyme and the PSP intron region was 
digested with SalI restriction enzyme. The XhoI digested promoter was purified 
via ethanol precipitation and then digested with calf intestinal phosphatase (CIP) 
enzyme in order to remove phosphate groups to prevent the XhoI cut vector from 
re-ligating to itself in the ligation step. After CIP digestion, the PSP 1.5 kb 
promoter was PCR purified. While the PSP 1.5 kb promoter was undergoing the 
various digestions, the PSP intron region was gel purified using the QIAquick Gel 
Extraction Kit. The purified PSP 1.5 kb promoter and the purified PSP intron 
region were ligated together and incubated overnight at 16 °C. The ligation 
reaction was transformed into TOPO 10 DH5-! competent cells and plated on LB 
plates containing ampicillin. Colonies were inoculated the next day and prepped 
for screening the PSP intron region using the Promega Wizard Plus SV 
Minipreps DNA Purification System. Miniprep samples were digested with NheI 
enzyme to screen for the PSP intron insert in the PSP 1.5 kb promoter. Samples 
with correctly digested band lengths were sent to the DNAcore for sequencing. 
After the correct sequence was confirmed, the PSP promoter + intron sample 
was purified using the QIAfilter Midi Prep Kit. 
 
TRANSFECTIONS 
 Transfections allow testing of exogenous, functional DNA by introducing 
the DNA of interest into a mammalian cell type. A cationic lipid reagent is added 
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to a reaction containing the DNA of interest. The positive charge of the cationic 
lipid interacts with the negatively charged DNA backbone, and the positive 
charge of the lipids allows the DNA-lipid complex to cross the negatively 
charged, hydrophobic cell membrane [101]. The promoter activity of the amylase-
1, NUPR1, PSP promoter (non-mutant and mutant), and PSP promoter + intron 
clones were tested by transfecting each DNA into mammalian cell lines. Each 
promoter had been cloned adjacent to the luciferase coding sequence, such that 
activation of the promoter stimulates luciferase enzyme expression, which is 
easily measured.  
Amylase-1 was transfected into ParC5, 3T3-L1, and JEG-3 cell lines. 
ParC5 cell type is an immortalized rat parotid acinar cell line, 3T3-L1 cell type is 
a mouse embryonic fibroblast cell line, and JEG-3 cell type is a human 
choriocarcinoma cell line [102-104]. The NUPR1 promoter was tested in ParC10 
and 3T3-L1 cell types. ParC10 cell line is a slightly different immortalized rat 
parotid acinar cell line than ParC5. The transfection reagent used for amylase-1 
promoter and NUPR1 promoter experiments was lipofectamine. The optimized 
amylase-1 promoter transfection conditions for ParC5 cells, 3T3-L1 cells, and 
JEG-3 cells were as follows: cells were split into a six-well plate at 100,000 cells 
per well; the total DNA used for experiments testing amylase-1 promoter activity 
was 1500 ng; the DNA:lipofectamine ratio for was 2:3. The optimized NUPR1 
promoter transfection conditions for ParC10 cells were 250,000 cells per well in a 
six-well plate, 640 ng of total DNA was transfected, and the DNA:lipofectamine 
ratio was 1:8. The optimized conditions for 3T3-L1 cells were 100,000 cells per 
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well were plated in a six-well plate, 800 ng of total DNA was transfected, and the 
DNA:lipofectamine ratio was 1:4. Renilla luciferase was transfected at the same 
concentration in the amylase-1 promoter and NUPR1 promoter experiments and 
used as a measure of transfection efficiency.       
The PSP 2kb promoter (non-mutants and E-box mutants) and PSP 
promoter + intron DNA clones were tested in ParC10 cells, another immortalized 
rat parotid acinar cell line [105]. The transfection reagent used for experiments 
testing PSP 2kb promoter (non-mutant and E-box mutant) was FugeneHD. The 
optimized transfection conditions for these experiments were cells were plated at 
60,000 cells per well in a 24-well plate, the total DNA concentration transfected 
was 200 ng, and the DNA:FugeneHD ratio used was 1:8. Renilla was used as 
the measure of transfection efficiency in experiments testing E-box mutant PSP 2 
kb promoter activity until the renilla activity was repressed. Cypridina luciferase 
was tested as the measure of transfection efficiency, and Mist1 did not repress 
the values measuring Cypridina. Cypridina was then used in the remaining E-box 
mutant PSP 2kb promoter experiments and in all experiments testing PSP 
promoter + intron activity.   
 
FIREFLY LUCIFERASE, RENILLA LUCIFERASE, AND CYPRIDINA 
LUCIFERASE ASSAYS 
 All the promoter constructs used in the transient transfection assays were 
ligated into a vector containing the luciferase gene. The amount of luciferase 
protein synthesized is a measure of promoter expression [106]. After the 
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transfected cells were allowed to grow for 48 hours, the media was removed and 
passive lysis buffer was applied to each well. The lysates from each well were 
tested for promoter activity by performing luciferase assays. The firefly luciferase 
substrate was injected into each individual sample and the relative light units 
(RLU) were measured by a luminometer. Renilla luciferase substrate and 
cypridina luciferase substrates were injected into another set of the same 
samples to test transfection efficiency. The final promoter activity was measured 
as the ratio of firefly luciferase RLU values:renilla luciferase or cypridina 































CHARACTERIZING THE PROXIMAL PROMOTER OF THE AMYLASE I GENE 
 Alpha-amylase (Amy-1) is an important and abundant protein in saliva that 
helps digest starch to maltose and glucose [33]. The Amy-1 gene is highly 
expressed in fully differentiated parotid acinar cells [30]. Schibler et. al. 
determined and showed activation of the amylase 1 promoter region years ago 
[28]. Since then there has been little investigation into characterizing the Amy-1 
promoter region even though the protein is a major component in saliva. Recent 
experiments performed in the laboratory have found this region to be inactive, 
contradicting Schibler’s results. The goal of studying the Amy-1 promoter was to 
determine active regions upstream of the transcription start site. Determining the 
active promoter will allow future work to define transcriptional activator sites 
within this region. Previously, a colleague in the laboratory performed 
transfections in ParC5 cells testing the activity of the rat amylase I R2-R1 
promoter construct. The results from luciferase and renilla assays show this 
promoter region is less active than the negative control, pGL4.10; therefore, the 
promoter is inactive (Figure 4). Since the amylase I gene between the rat and 
mouse is conserved, mouse amylase I clones were made to test promoter 
expression.  
The amylase I promoter clones used in this work are listed in Table 1 and 
Figure 3. A 1,000 bp promoter region (R1) directly upstream of the transcription 
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start site was ligated into a pGL4.10 luciferase. The levels of promoter activity 
are determined by measuring luciferase expression. A 2,000 bp promoter region 
(R2) directly upstream of the 1,000 bp region was ligated into the R1 amylase I 
promoter clone.  
To test amylase I promoter activity, the mouse R1 and mouse R2-R1 
clones were transfected in ParC5, 3T3-L1, and JEG-3 cell lines. The harvested 
cell lysates were measured for promoter activity by luciferase assays and the 
transfection efficiency was measured by renilla luciferase assays. Promoter 
activity was determined by normalizing average luciferase values to average 
renilla luciferase values. As shown in Figure 5, mouse amylase I R1 promoter 
and mouse amylase R2-R1 promoter activity is less than the negative and 
positive controls. These results were demonstrated in three different cell lines 
confirming the amylase promoter regions tested were repressed. After seeing the 
repressed promoter activity, sequence analysis was done and identified multiple 
transcriptional repressor sites in the R1 region.  
Amylase promoter clones with the repressor sites removed were made for 
both the mouse and rat. A 900 bp promoter clone eliminated GFI1, ZEB1, and 
FREAC4 transcription factor binding sites. A 700 bp promoter clone eliminated 
GFI1, ZEB1, FREAC4, and two CHOP transcription factor binding sites (Figure 
3). Both promoter clones with these sites removed were ligated into the minimal 
promoter pGL4.23 luciferase vector. The sequences of each promoter clone 
were confirmed. The purified amylase I promoter clones were transfected in 
ParC5, 3T3-L1, and JEG-3 cell lines to test promoter activity. Data obtained from 
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luciferase and renilla assays show amylase promoter activity is still repressed 
compared to the promoterless negative control, pGL4.23, in each cell line tested 
(Figure 6). These data indicate that the regulatory region of amylase I gene are 
outside the 3,000 bp region tested. Initial work with the parotid amylase promoter 
looked at its endogenous expression and found the promoter to be inactive. Even 
though an unpublished observation found a 300 bp amylase promoter to be 
active, this small promoter region would not benefit the goal of identifying active 
sites. The data agree with the literature that the mouse amylase promoter 
















Figure 3: Amylase I Promoter Clones 
 
Figure 3: A diagram of the amylase I promoter regions used in transfection 
experiments. The transcription start sites for the parotid and liver are shown. The 
constructs for the 1kb promoter, represented here as R1, and the 2kb promoter 
region added to the 1kb promoter clone, represented here as R2, are shown 
ligated to the pGL4.10 luciferase vector. The transcriptional repressor binding 





















Figure 4: Rat Amylase promoter activity in ParC5 cells 
 
Figure 4: Testing the activity of rat amylase R2-R1 promoter. The activity of rat 
amylase I promoter is compared to a negative control, pGL4.10, and a positive 
control rat PSP 500 bp promoter. The rat amylase promoter has lower activity 
compared to the negative and positive controls. N = 1 independent experiment 



































Figure 5: Mouse amylase I promoter activity in different cell lines.  
 
Figure 5: Testing the activity of mouse amylase R1 and mouse amylase R2-R1 
promoter. The activity of mouse amylase I promoter is compared to a 
promoterless negative control, pGL4.10, and a positive control rat PSP 500 bp 
promoter. Each cell line demonstrates low activity of the amylase I promoters. 

































Figure 6: Activity of mouse and rat amylase I promoter with repressors 
removed in different cell lines. 
 
Figure 6: Testing the activity of mouse amylase 900 bp promoter and mouse 
amylase 700 bp promoter. The activity of mouse amylase I promoter is compared 
to a negative control, pGL4.23. The activity of the amylase I promoters is still 
very low when transcriptional repressor binding sites are removed in three 




































CHARACTERIZING THE NUPR1 PROMOTER REGION 
 The next goal was to characterize the NUPR1 promoter by testing the 
predicted regulatory interactions of this gene. The NUPR1 promoter clone used 
in the following experiments contains a 1305 bp proximal promoter region 
directing expression of luciferase (Figure 7). Cited2 + p300 and IRF2 + PCAF 
were predicted to stimulate gene expression based on the hypothetical network 
described above (Figure 2). The NUPR1 promoter clone was co-transfected with 
Cited2 + p300 into ParC10 and 3T3-L1 cell lines. The promoter was also co-
transfected with IRF2 + PCAF in 3T3-L1 cells. Luciferase and renilla assays were 
performed to test promoter activity. NUPR1 promoter activity was determined by 
normalizing luciferase to renilla.  
The NUPR1 promoter was not active in the ParC10 cell line (Figure 8A). 
The promoter activity was only a little higher than the promoterless pGL4.10 
negative control, but not high enough to confirm its activity in ParC10 cells. Even 
though the promoter was inactive, it was analyzed using ANOVA and no 
significant change in NUPR1 promoter activity was found when Cited2 + p300 
cDNAs were co-transfected in ParC10 cells (p = 0.0961).  
The NUPR1 promoter was active when transfected in the 3T3-L1 cell line. 
A one-tailed T-test calculated a significant increase in promoter activity when 
comparing the promoterless pGL4.10 negative control to the NUPR1 promoter, p 
= 0.05. A one-tailed T-test determined no significant change in NUPR1 promoter 
activity when Cited2 + p300 were co-transfected, p = 0.2058 (Figure 8B).  
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The second interaction tested was the effect of IRF2 + PCAF transcription 
factors on NUPR1 promoter activity. Again, the NUPR1 promoter exhibited 
higher activity than the promoterless pGL4.10 negative control in 3T3-L1 cells 
(Figure 9). However, the ANOVA calculated a non-significant change in NUPR1 
promoter activity when IRF2 + PCAF are co-transfected in 3T3-L1 cells, p = 
0.1409. The conclusion from this data is the NUPR1 promoter is not being 
activated by either Cited2 + p300 or IRF2 + PCAF in two different cell lines; 

















Figure 7: NUPR1 promoter clone 
 
Figure 7: A picture representing the NUPR1 gene and promoter region. The 
transcription start site and the three exons of the NUPR1 gene are shown. The 
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Figure 8: Effect of Cited2 + p300 on NUPR1 promoter activity in ParC10 and 
3T3-L1 cell lines. 
A. ParC10 cells  
 
B. 3T3-L1 cells  
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Figure 8: A: The NUPR1 promoter clone was co-transfected with Cited2 + p300 
expression plasmids into ParC10 cells. Promoter activity was determined by 
normalizing raw luciferase to raw renilla luciferase values. ANOVA did not show 
any significant changes between any of the groups, p = 0.0961. Therefore, 
Cited2 + p300 do not activate NUPR1 promoter in ParC10 cells. The pGL4.10 
control was set to 100%. N = 4 independent experiments done with triplicate 
wells. B: The NUPR1 promoter clone alone was activated in 3T3-L1 cells and a 
Mann-Whitney one-tailed t-test calculated a significant activation, p = 0.05. The 
NUPR1 promoter clone was co-transfected with Cited2 + p300. One-tailed T-test 
of NUPR1 calculated a p-value that is not significant. This statistical analysis 
proves NUPR1 promoter is not activated by Cited2 + p300 in 3T3-L1 cells. The 
pGL4.10 control was set to 100%. N = 3 independent experiments done with 













Figure 9: Effect of IRF2 + PCAF on NUPR1 promoter activity in 3T3-L1 cells. 
 
Figure 9: The NUPR1 promoter-luciferase clone was co-transfected with IRF2 + 
PCAF cDNAs in 3T3-L1 cells. Promoter activity was determined by normalizing 
raw luciferase to raw renilla luciferase values. ANOVA did not show any 
significant changes between any of the groups, p = 0.1409. Therefore, IRF2 + 
PCAF do not activate NUPR1 promoter in 3T3-L1 cells. The pGL4.10 control was 
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CHARACTERIZING PSP PROMOTER REGION 
 Parotid secretory protein (PSP) is an abundant protein in saliva and has 
been suggested to have antibacterial properties that protect the oral cavity. 
Research has focused on PSP protein function, but much work remains to be 
done to characterize PSP gene regulation. The PSP gene is a marker of parotid 
differentiation and contains regulatory regions in its promoter region that need to 
be characterized. One transcription factor that was identified in the hypothetical 
transcription factor network was Mist1, and it was predicted to act on PSP 
(Figure 2). Mist1 is a transcriptional activator that binds the E-box motif 
CANNTG, and these sites were identified in the rat PSP promoter region. The 
first goal was to determine if Mist1 activates the rat PSP 2 kb promoter region. 
The second goal was to determine if mutating E-box DNA binding sites in the rat 
PSP 2kb promoter would prevent activation. 
The rat PSP promoter clones, non-mutated and mutated, are depicted in 
Figure 10 and Figure 11. The non-mutated PSP promoter clone was previously 
made in the laboratory and contains a 2,000 bp proximal promoter region next to 
the transcription start site of the PSP gene. The region was PCR amplified and 
then ligated into a pGL4.10 luciferase vector. The correct sequence was 
confirmed, the DNA was purified, and transfection experiments were performed 
to test promoter activity.  
 In addition, sequence analysis found E-box sites, or Mist1 binding sites, in 
the pGL4.10 luciferase vector and in the 2,000 bp promoter region (Figure 11). 
These sites were mutated following the recommended protocol in the 
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QuikChange II Site-directed Mutagenesis Kit provided by Stratagene. The correct 
sequence was confirmed, the DNA was purified, and transfection experiments 
were performed to test promoter activity. The non-mutated and mutated promoter 
DNA clones were co-transfected with rat Mist1 cDNA in ParC10 cells. The cell 
lysates were tested for promoter activity and transfection efficiency by luciferase 
assays and renilla luciferase assays, respectively.  
The data show that the non-mutated PSP 2kb promoter and the mutant 
clones, PSP2kb-pGL4.10$M and PSP2kb$M-pGL4.10$M, were active in ParC10 
cells (Figures 10 and 11). Samples co-transfected with Mist1 had repressed 
activity (Figure 12). The promoter activity was repressed by at least one-half or 
more when Mist1 was co-transfected as compared to the promoter activity 
without Mist1 co-transfected. Two-tailed T-test calculated nonsignificant 
repression for PSP2kb-pGL4.10$M (p = 0.1230) and significant repression for 
PSP2kb$M-pGL4.10$M (p = 0.0132). The two-tailed T-test for the non-mutated 
PSP 2kb promoter did not calculate a significant repression (p = 0.0822), but 
promoter activity appears to decrease by about one-half when Mist1 is co-
transfected as compared to the control PSP 2kb promoter. Based on these 
results, Mist1 alone does not activate the PSP gene through the promoter region; 
therefore, this does not support the hypothetical network of Mist1 activating PSP 
through the promoter region.      
Mist1 can activate gene expression by binding as a heterodimer with 
another bHLH protein. Tcf3, or E2A, has been shown to bind DNA as a 
heterodimer with Mist1 and bind E-box sites [84]. The first goal was to 
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demonstrate that a combination of Mist1/Tcf3 transcription factors did not 
activate the PSP promoter. This goal was achieved by co-transfecting a 
combination of rat Mist1 cDNA and rat Tcf3 cDNA with the rat PSP 1.5 kb 
promoter construct (Figure 10) in the ParC10 cell line. The results from this data 
observe no change in promoter activity (Figure 14). A one-tailed T-test calculated 
a p-value of 0.1735, indicating there was no effect of the Mist1/Tcf3 transcription 
factor combination. This result supported the hypothesis that the combination of 

















Figure 10: rat PSP gene with indicated promoter clone constructs.  
 
Figure 10: A diagram of the PSP gene. Exons 1 – 4 are labeled and the red 
arrow indicates the transcription start site. The PSP 1,500 bp promoter and the 
PSP 2,000 bp promoter constructs are shown ligated to a pGL4.10 luciferase 
vector. The PSP 2,000 bp promoter clone was used in co-transfection 


















Figure 11: A diagram of the PSP 2kb promoter ligated in pGL4.10 luciferase 
vector. The consensus E-box DNA site mutated in these clones is CANNTG. 
Sites A,B, and C are located in pGL4.10 and sites 3 and 4 are located in PSP 
2kb promoter. A: The PSP2kb-pGL4.10$M clone has E-box sites A, B, and C 
mutated in the pGL4.10 luciferase vector, and the PSP 2kb promoter fragment is 
ligated to this mutated vector. B: The PSP2kb$M-pGL4.10$M clone has E-box 
sites A, B, and C mutated in the pGL4.10 luciferase vector, and E-box sites 3 and 





Figure 12: Testing the effect of Mist1 on non-mutant and E-box mutant PSP 
promoter. 
 
Figure 12: Non-mutated PSP promoter and E-box mutated PSP promoter 
activity by Mist1. Promoter activity is measured by the percent 
luciferase:cypridina ratio and compared to non-mutated PSP promoter activity 
(set to 100%). ANOVA found significant changes in the data (p = 0.0205), so two-
tailed paired T-tests were performed to distinguish changes in promoter activity 
when Mist1 was co-transfected. N = 2 independent experiments done with 
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CHARACTERIZATION OF PSP PROMOTER + INTRON REGION 
 Mist1 did not activate the PSP proximal promoter, so I investigated 
another way this gene may be activated by Mist1. Mist1 has been shown to 
activate gene expression by binding to E-box sites in the first intron of genes [48].  
The next goal was to determine if a combination of Mist1/Tcf3 transcription 
factors activate PSP through intron regions of the gene. Sequence analysis of 
the rat PSP gene, exons and introns, found E-box binding sites in the second, 
third, and fifth introns (Figure 13). The region between exon 2 and exon 4 was 
successfully PCR amplified. This region contains E-boxes in the second and third 
introns. Amplifying the region containing E-box sites in the fifth intron was 
unsuccessful, so attempts to make this clone were halted. The intronic amplified 
region was digested with SalI restriction enzyme, and the PSP 1.5 kb promoter 
clone was digested with XhoI restriction enzyme. When the intronic region was 
ligated into the PSP 1.5kb promoter clone, the SalI sites and the XhoI sites at the 
cloning region were abolished. The only issue with cloning with these enzymes 
was the risk that the intronic region would be ligated in the opposite orientation; 
however, DNA sequence analysis confirmed a clone that contained the inserted 
region in the correct, or forward, orientation. After sequence confirmation, this 
clone was purified and used in transfection experiments.   
A combination of rat Mist1 cDNA and rat Tcf3 cDNA was co-transfected 
with the PSP promoter + intron clone into ParC10 cells. This experiment was 
done simultaneously when testing the effect of Mist1 and Tcf3 on the PSP 1.5 kb 
promoter. Performing these experiments in unison resulted in the PSP 1.5 kb 
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promoter to be used as a good negative control to compare to the PSP promoter 
+ intron results. The results from testing the effect of the transcription factor 
combination determined that PSP promoter + intron activity is increased by about 
2-fold (Figure 14). A one-tailed T-test calculated a significant change in PSP 
promoter + intron activity when Mist1/Tcf3 was co-transfected, p = 0.0136. These 
results conclude that PSP can be activated through the second and third intron 
regions by a combination of Mist1/Tcf3. This conclusion supports the hypothesis 
that a Mist1/Tcf3 combination can activate PSP through intronic binding sites.  
 The next goal was to determine if there is a specific effect from Mist1 
alone or Tcf3 alone. ParC10 cells were transfected with PSP 1.5 kb promoter or 
PSP promoter + intron and Mist1 alone, Tcf3 alone, or a Mist1/Tcf3 combination. 
Luciferase assay RLU values were normalized to Cypridina RLU values to 
determine promoter activity. ANOVA of PSP 1.5 kb promoter group was 
significant, p = 0.0001 (Figure 15). Mann Whitney two-tailed T-test comparing the 
control, PSP 1.5 kb alone, to the different experimental groups was performed.  
There was no change in promoter activity by Tcf3 when compared to the 
negative control, promoter alone, and the T-test calculated the effect of Tcf3 
alone was not significant, p = 0.3429. Mist1 repressed promoter activity, and this 
repressive effect of Mist1 was significant, p = 0.0286. The combination of 
Mist1/Tcf3 repressed the promoter as well, and the repression by Mist1/Tcf3 was 
significant as calculated by the T-test, p = 0.0286. As observed above, the effect 
of Mist1 and the combination of Mist1/Tcf3 repressed transcription from the PSP 
1.5 kb promoter, and transfection of Mist1 alone is sufficient for repression.  
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A Mann-Whitney test using a two-tailed T-test was used to test 
significance between the control group, PSP promoter + intron without Mist1, 
Tcf3, or the combination, and the experimental groups. The effect by Tcf3 alone 
appeared to increase luciferase activity, but the Mann-Whitney test calculated a 
non-significant p-value for the effect of Tcf3 on PSP promoter + intron (p = 
0.3429). Mist1 did not change PSP promoter + intron activity, and the Mann-
Whitney test calculated p > 0.9999 for the effect of Mist1 on PSP promoter + 
intron. However, PSP promoter + intron co-transfected with the combination of 
Mist1/Tcf3 exhibited a dramatic increase in activity, and had a significant p-value 
from the Mann-Whitney two-tailed T-test, p = 0.0286 (Figure 15). Based on this 
data there is not a specific effect from Mist1 alone or Tcf3 alone on PSP 
promoter + intron activity. This data further confirms results that a combination of 
Mist1 and Tcf3 activates PSP through the second and third intron regions. The 
data support the hypothetical network that Mist1 does interact with PSP. The 
novelty of this interaction is that Mist1 activates PSP when the E-box protein Tcf3 









Figure 13: PSP promoter + intron clone 
 
Figure 13: The top of the figure shows the first four exons (labeled 1 - 4 
underneath) and the first three intron regions of the PSP gene. The E-box 
binding sites in the intronic regions are labeled. The bottom of the figure is the 
PSP promoter + intron clone used in transfection experiments. The dotted lines 
indicate the PSP intron region that was amplified from rat genomic DNA. The 
intronic region was ligated into the PSP 1.5 kb promoter clone depicted in figure 
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Figure 14: Testing the effect of Mist1/Tcf3 combination on PSP promoter 
and PSP promoter + intron activity. 
 
Figure 14: A: PSP 1.5 kb promoter activity without and with Mist1/Tcf3 co-
transfected in ParC10 cells. Promoter activity was measured as the percentage 
of luciferase/cypridina. The promoter alone was set at 100 and compared to the 
promoter co-transfected with the Mist1/Tcf3 combination. There was no change 
in promoter activity from the Mist1/Tcf3 combination and, a one-tailed T-test 
calculated an insignificant change in promoter activity, p = 0.1735. B: PSP 
promoter + intron without and with a Mist1/Tcf3 combination co-transfected in 
ParC10 cells. Promoter + intron activity was measured as the percentage of 
luciferase/Cypridina. The PSP promoter + intron alone was set to 100 and 
compared to the promoter + intron co-transfected with a Mist1/Tcf3 combination. 
The promoter + intron activity increased almost two-fold, and a one-tailed T-test 
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calculated a significant change in activity, p = 0.0136. N = 7 independent 






















Figure 15: Testing the specific effect of Tcf3 alone or Mist1 alone on PSP 
promoter + intron activity. 
 
 Figure 15: A: PSP 1.5 kb promoter activity without any transcription factor and 
with Tcf3 alone, Mist1 alone, or a Mist1/Tcf3 combination. The control group, 
promoter alone, was set to 100 and each experimental group was compared to 
this control. ANOVA calculated significant changes among the group, p = 0.0001. 
Mann-Whitney two-tailed T-test was calculated between the control and 
individual experimental groups. Tcf3 did not have an effect on the promoter, p = 
0.3429. Mist1 alone and the Mist1/Tcf3 combination had significant repressive 
effects on the promoter, p = 0.0286 for both. B: PSP promoter + intron activity 
without any transcription factor and with Tcf3 alone, Mist1 alone, or a Mist1/Tcf3 
combination. The control group, promoter + intron alone, was set to 100 and 
each experimental group was compared to this control. A Mann-Whitney two-
tailed T-test calculated a significant change when a combination of Mist1/Tcf3 is 
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co-transfected with PSP promoter + intron, p = 0.0286. N = 4 independent 























MOUSE AMYLASE 1 PROMOTER IS INACTIVE IN DIFFERENT CELL TYPES 
 Salivary amylase is an abundant enzyme produced primarily from serous 
cells of the parotid that hydrolyzes food starch into maltose and glucose [32, 33]. 
Salivary amylase affects oral biofilms and is a component of the acquired enamel 
pellicle (AEP) [34, 36, 37]. Amylase has two genes located on mouse 
chromosome three [25, 26]. The first locus corresponds to Amy-1, which is 
expressed in the salivary gland, and the second locus is Amy-2, which is 
expressed in the pancreas. The Amy-1 gene is expressed as two different mRNA 
products with one in the parotid gland and the other in the liver. Amy-1 has two 
promoters with tissue specific expression in the parotid gland and in the liver [28]. 
Testing endogenous promoter activity and measuring amylase mRNA levels 
determined the location of the parotid and liver promoters and their activity [26, 
28, 31].  
 Stable and transient transfection experiments performed in cell lines 
lacking endogenous Amy-1 observed that the PL was active in all cell types, but 
that the PP did not show activation in any of the cell types tested [28]. In an 
isolated comment about unpublished data it was claimed that deletion of the 5’ 
flanking region of PP observed that removing nucleotides upstream of position -
300 relieved transcriptional repression.  
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The amylase parotid promoter region was determined by analysis of the 
mRNA start sites, but little work has been done to characterize this region. The 
lack of research defining the regulatory regions of amylase is surprising because 
amylase is one of the major proteins in saliva and is a terminal differentiation 
marker of the parotid gland [30]. The goal of this research was to determine 
transcriptionally active promoter regions. Clones were made and tested in 
transient transfection, which experiments contained up to 3 kbp of the amylase 
parotid-specific promoter. Two clones were made and tested that had 
transcriptional repressor binding sites removed from the 5’ end of the 1kb 
proximal promoter region. Each amylase promoter clone was transfected in three 
different cell lines, ParC5, 3T3-L1, and JEG-3.  
 All amylase parotid promoter clones were repressed compared to the 
promoterless negative control, pGL4.10, in each cell line. The repression of the 
1kb proximal promoter was expected because Schibler et. al. observed the same 
result. The idea that activating elements could be further upstream from a 
proximal promoter led to cloning an additional 2kbp region upstream of the 
proximal promoter. Again, adding this 2kbp promoter region did not activate 
amylase in any cell type this clone was transfected in. The results from testing 
the 900 bp and 700 bp promoter clones also exhibited repression in all cell types. 
This was unusual because removing transcriptional repressor sites from the 
region should relieve any repressive effects. The amylase promoter was 
repressed in multiple cell types even after testing a region upstream of the 
suggested proximal promoter region and by removing transcriptional repressors. 
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The conclusion from these amylase 1 experiments is that amylase is being 
activated by another region outside of the 3 kb region tested or cryptic repressor 
binding sites are present within the smallest (700 bp) promoter tested. Future 
work cloning even further upstream regions might find an active promoter. Once 
an active region is found analysis can be performed to characterize and define 
transcriptional activators involved in amylase 1 activation. 
 
CONFIRMING TRANSCRIPTIONAL PATHWAYS IN THE HYPOTHETICAL 
TRANSCRIPTION FACTOR NETWORK OF PAROTID GLAND 
DIFFERENTIATION 
 Many molecular mechanisms are involved in parotid gland differentiation, 
and the role of transcription factors was of interest in this research. Rat parotid 
gland mRNA was analyzed in the laboratory by Dr. Srirangapatnam, and the 
results showed that many transcription factors are tightly regulated during parotid 
gland differentiation. Testing mRNA from embryonic stages to postnatal stages 
determined that a single transcription factor could be expressed at variable levels 
throughout development. It appeared that related transcription factors were 
expressed at the same time point, and this allowed us to determine four distinct 
stages of differentiation. Each stage was examined to find transcription factors 
that had increased levels of expression as genes of interest increased 
expression levels. Once these patterns of expression were determined, the 
transcription factors and genes were entered into the IPA program to model 
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predicted interactions [24]. A hypothetical transcription factor network of parotid 
gland differentiation was created using IPA (Figure 2). 
 The focus of the next part of my research was to validate some of the 
pathways of the hypothetical transcription factor network. One of the interactions 
tested was the effect of a combination of Cited2 and p300 co-factors and a 
combination of IRF2 transcription factor and PCAF co-factor on NUPR1 promoter 
activity. The other interaction tested was the effect of Mist1 transcription factor on 
PSP promoter activity. The goal was to confirm interactions by performing 
transient transfection experiments in parotid acinar cell types. Confirming 
interactions would also aid in characterizing the promoter regions of interest.  
 
NUPR1 PROXIMAL PROMOTER IS NOT ACTIVATED BY CITED2/P300 OR 
IRF2/PCAF COMBINATIONS 
 The NUPR1 protein is a transcription factor that binds to DNA to regulate 
gene expression in the exocrine cells of various tissues such as the salivary 
glands, stomach, colon, liver, and kidneys [38-40]. NUPR1 was the first promoter 
tested from the hypothetical network. The goal was to validate two separate 
interactions with the NUPR1 promoter. These interactions included determining 
the effect of the combination of Cited2 and p300 co-factors and the combination 
of IRF2 and PCAF on NUPR1 promoter activity. The hypothesis tested was that 
Cited2/p300 and IRF2/PCAF would activate the NUPR1 promoter. Confirming 
these transcription factor interactions would support the hypothetical transcription 
factor network of parotid differentiation. 
)+"
The first combination of co-factors tested to determine their effect on the 
NUPR1 promoter was Cited2 and p300. Cited2 belongs to a family of genes 
known as CITED (CBP/p300 interacting transactivators with ED-rich termini) [49, 
50]. CITED proteins do not bind DNA, but serve as transcriptional co-activators. 
Cellular Cited2 binds tightly to the CBP/p300 transcription complex, and this 
interaction is predicted in the hypothetical network (Figure 6). The nuclear 
phosphoprotein, p300, is widely expressed and homologous to the cAMP 
response element binding protein (CBP), [54, 55]. p300 is a co-activator that links 
DNA-bound transcriptional activators to the basal transcription machinery. It has 
histone acetyltransferase (HAT) activity that is involved in modifying chromatin 
structure within gene promoters, and the HAT activity allows p300 to increase 
DNA binding efficiency of p300-interacting transcription factors [56, 57]. Both of 
these histone-modifying actions result in more efficient transcription of target 
genes.   
The effect of Cited2 and p300 on NUPR1 promoter was tested in two 
different cell lines. First, Cited2 and p300 were co-transfected with the NUPR1 
promoter in ParC10 cells. The NUPR1 promoter alone was inactive in this cell 
line, so the effect of Cited2 and p300 could not be determined. The ParC10 cell 
line is an undifferentiated acinar cell type, so important regulators of NUPR1 
gene expression might not be present [102]. After determining the NUPR1 
promoter was inactive in ParC10 cells, Cited2 and p300 were co-expressed with 
the NUPR1 promoter in an alternative cell line, 3T3-L1. The NUPR1 promoter 
alone was active in the 3T3-L1 cell line, so all future experiments testing NUPR1 
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promoter activity used these cells. Even though the promoter was active as 
compared to the promoterless negative control, pGL4.10, there was no effect of 
Cited2 and p300 on NUPR1 promoter activity. An example from the literature of 
Cited2 repressing gene expression is on the NF-%B gene [107]. One of the ways 
it represses NF-%B is by sequestering p300 and inhibiting it from binding p65, an 
important activator of NF-%B. A similar mechanism might be happening with 
Cited2 and p300 resulting in no change in activity, instead of repression, of the 
NUPR1 promoter. However, there are many more instances of Cited2 and p300 
working to enhance gene expression, so these transcriptional co-factors appear 
to not be involved in NUPR1 expression. The conclusion from the results did not 
support the hypothetical transcription factor network that Cited2 and p300 
activate the NUPR1 promoter. 
 The next combination of transcription factors tested was the effect of IRF2 
and PCAF on NUPR1 promoter activity. IRF2 belongs to the interferon regulatory 
(IRF) transcription factor family and binds DNA through its N-terminal domain 
[62, 67]. IRF2 binds various DNA elements such as interferon responsive 
element (IRF-E), the interferon consensus sequence (ICS), and the positive 
regulatory domain I (PRDI) of the IFN-" gene [63, 64, 66]. IRF2 can function as a 
transcriptional repressor or activator [65].  
The transcriptional cofactor p300/CBP-associated factor (PCAF) functions 
as a co-activator of transcription, and it has histone acetyltransferase (HAT) 
activity [73-75]. PCAF has been shown to have various functions such as acting 
as a tumor suppressor and being involved in differentiation [73, 82]. IRF-2 
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recruits PCAF to enhance its own binding to the ICS [83]. The direct interaction 
of IRF-2 and PCAF was shown to increase the histone H4 gene promoter 
activity. Since this promoter was activated by IRF-2 and PCAF, this supported 
testing the effect of these transcription factors on NUPR1 promoter expression.  
IRF-2 and PCAF were co-transfected with the NUPR1 promoter in the 
3T3-L1 cell line. As mentioned above, the NUPR1 promoter was active in this cell 
line as compared to the promoterless negative control, pGL4.10. However, co-
expression of IRF2 and PCAF did not increase NUPR1 promoter activity. It has 
been noted in the literature that IRF2 is acetylated by PCAF in a growing cell 
type, and acetylation of IRF2 is required for promoter activation [108]. The 3T3-
L1 cells used in these experiments are an undifferentiated pre-adipocyte cell 
type. Since acetylation of IRF2 only happens in growing cells, this transcription 
factor might not be sufficiently acetylated by PCAF in the experiments testing 
NUPR1 promoter activity. Stimulating 3T3-L1 cells in future transfection 
experiments might exhibit NUPR1 promoter activation from IRF2 and PCAF. 
 
THE PSP PROXIMAL PROMOTER IS NOT ACTIVATED BY MIST1 
TRANSCRIPTION FACTOR IN THE PARC10 CELL LINE. 
 The next interaction tested to validate the hypothetical transcription factor 
network was the effect of Mist1 on the PSP promoter. PSP is highly expressed in 
acinar cells of the adult parotid gland [14]. Mist1 is a bHLH transcription factor 
expressed in many tissues that binds to E-box sequences, -CANNTG-, as a 
homodimer or heterodimer [84-86]. The hypothesis was Mist1 would activate the 
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PSP promoter. The goals were to first test PSP promoter activation from co-
transfection of Mist1 cDNA. The second goal was to mutate Mist1 binding sites, 
or E-box binding sites, in the PSP promoter to determine promoter activity.  
  There were two objectives for testing the effect of Mist1 on PSP promoter 
activity. The first goal was accomplished by co-transfecting PSP promoter DNA 
with Mist1 cDNA in ParC10 cells. The second goal was accomplished by 
mutating –CANNTG- E-box binding sites in the PSP 2kb promoter construct 
(Figure 11). The non-mutant and mutant constructs were co-transfected with 
Mist1 cDNA in ParC10 cells. The non-mutated PSP promoter and the E-box 
mutated PSP promoter constructs were all repressed by Mist1. One reason this 
repression might have happened is that Mist1 homodimers repress gene 
expression. An example is MyoD repression by Mist1 homodimers during 
myogenesis [109]. The Mist1 homodimer directly binds to E-box sequences in 
the MyoD promoter and subsequently represses gene expression. In the 
experiments testing PSP promoter activity, Mist1 does regulate the PSP 
promoter, but not in the expected direction. This may be one aspect of controlling 
the timing of PSP expression during development. The conclusion was the 
results do not support the hypothetical network that Mist1 activates the PSP 
promoter. This conclusion led us to determine other ways Mist1 could be 
activating PSP.  
 
PSP IS ACTIVATED BY A COMBINATION OF MIST1 AND TCF3 
TRANSCRIPTION FACTORS THROUGH THE SECOND AND THIRD INTRON 
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 As mentioned above, Mist1 repressed the PSP promoter, and the 
repression might have been due to formation of Mist1 homodimers. In contrast to 
this finding, Mist1 has been reported to activate genes by forming heterodimers 
with the E-box protein Tcf3, or E2A [84]. The E2A gene encodes two class I 
bHLH transcription factors, E12 and E47, and binds E-box consensus sequences 
as does Mist1 transcription factor [84-86, 95]. The E2A transcription factor is 
expressed in various tissues and can act as a transcriptional activator or 
repressor depending on its binding partner and other co-activators or co-
repressors [86]. The finding that Mist1 and Tcf3 can form heterodimers led to the 
hypothesis that co-transfecting a combination of Mist1 and Tcf3 will activate the 
PSP promoter.  
To test the hypothesis, transient transfection experiments were performed 
testing the effect of the combination of Mist1 and Tcf3 transcription factors on 
PSP promoter activity in ParC10 cells. The PSP promoter was not activated by 
the combination of transcription factors. The conclusion from this result was Mist 
and Tcf3 are not acting through the promoter region of PSP. Again, PSP is not 
exhibiting activation even though Mist1 has a dimerization partner that has been 
shown to activate gene expression. The next step was to find another way to 
express the PSP promoter.  
One group found the gene Mindbomb-1 was activated by Mist1 through 
the first intron [48]. The PSP gene was analyzed and E-box binding sites were 
found in the second, third, and fifth introns of PSP. The evidence that Mist1 
activates a gene through the first intron, and the analysis of the PSP gene helped 
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formulate the hypothesis that a Mist1 and Tcf3 transcription factor combination 
activates PSP through the intron regions. The PSP promoter + intron clone was 
made by ligating a PCR amplified region between exon two and four into the PSP 
1.5 kb promoter clone (Figures 10 & 13). This clone was co-transfected with 
Mist1 and Tcf3 cDNA in ParC10 cells, and promoter + intron activity was 
determined by performing luciferase and cypridina assays. The data observed an 
increase in PSP promoter + intron activity when Mist and Tcf3 were co-
transfected. The hypothetical network was supported by this result. A novel 
discovery from this result was Tcf3 interacts with Mist1 to activate the PSP 
promoter. This hypothetical network did not predict this interaction, and the 
conclusion was that Mist1 required Tcf3 to promote PSP gene expression.  
Since the combination of Mist1 and Tcf3 promoted PSP expression, the 
next goal was to test the specific effect of Mist1 alone and Tcf3 alone. The PSP 
1.5 kb promoter without the intron region was used as a negative control in these 
experiments because it was found to have no change in activity with a Mist1/Tcf3 
combination. The promoter exhibited no change in activity from Tcf3 alone, which 
was a new finding, and from the combination of Mist1 and Tcf3, which was 
expected. Mist1 alone repressed PSP 1.5 kb promoter activity, which was 
consistent with the results described above. The results for the PSP 1.5 kb 
promoter made it a valid control to compare the effects on the PSP promoter + 
intron construct. The PSP promoter + intron was slightly activated by Tcf3 alone, 
but not significantly, and it exhibited no change in activity when Mist1 alone was 
co-transfected. Again, the PSP promoter + intron construct was activated by the 
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combination of Mist1 and Tcf3 through the second and third introns, further 
supporting the hypothetical network with the new finding that Mist1 requires Tcf3 
for PSP gene activation. The work reported that used a Mist1 knockout mice 
model supports the importance of Mist1 and the effect it has on secretory granule 
formation and the content of secretory granules [93, 94]. PSP is a protein found 
in parotid acinar cell secretory granules [102]. PSP activation by Mist1 could be 
happening just before or simultaneously with secretory granule formation, 




 Even though many interactions tested did not confirm the hypothetical 
transcription factor network of parotid differentiation, activation of the PSP 
promoter + intron clone by Mist1 was confirmed. The next step after determining 
this activation will be to confirm the Mist1/Tcf3 binding sites in the intron region 
by site-directed mutagenesis. This will validate that activation is from these 
transcription factors acting directly at the binding site, and it can determine if 
there is a preferential binding site. This future work will be done in the laboratory, 
but there could be clinical use of confirming transcriptional interactions. 
 Parotid gland ablation from head and neck radiation therapies, infection, 
inflammation, medications, and Sjögren’s Syndrome (SS) can be debilitating [5, 
15]. Patients suffering from any of these conditions lose proper parotid gland 
function and will develop xerostomia [17]. This can lead to a declining oral health 
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resulting in periodontitis and cavities. Determining the genes involved in parotid 
differentiation could aid in the development of therapeutics involving molecular 
targets and in developing improved diagnostics. Although numerous transcription 
factor pathways still need to be validated, the successful confirmation of PSP 
promoter activation by Mist1 and Tcf3 is a stepping-stone to the development of 
gene therapies and enhancing diagnostic tools. My work, together with other 
reports, suggests that transgenic expression of Mist1 may help maintain parotid 
function in patients.          
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